\-\ Texto\\:\\ \ \(0\)\
\-\ vs\\:\\ \\ bp\\ 130\\/80\\ mmhg\\,\\ hr\\ 78\\ bpm\\,\\ rr\\ 16\\ respirations\\ \\/\\ min\\,\\ \ \(0\)\
\-\ general\\:\\ 62\\"\\ african\\ american\\ female\\ weighing\\ 241\\ lbs\\.\\ \\(44\\.1\\ bmi\\)\\ in\\ no\\ acute\\ distress\\.\\ \ \(0\)\
\-\ skin\\:\\ moist\\,\\ regular\\ texture\\ and\\ color\\,\\ no\\ evidence\\ of\\ nodules\\ petechiae\\ edema\\ or\\ changes\\ in\\ pigmentation\\.\ \(0\)\
\-\ head\\:\\ normocephalic\\ and\\ atraumatic\\,\\ without\\ any\\ lesions\\ or\\ tenderness\\.\ \(0\)\
\-\ eyes\\:\\ prescription\\ glasses\\ noted\\.\\ bl\\ no\\ lid\\ lag\\ or\\ edema\\.\\ bl\\ conjunctiva\\ pink\\,\\ non\\-inflamed\\.\\ perrla\\.\\ sclera\\ white\\ and\\ anicteric\\.\\ eomi\\,\\ with\\ visual\\ fields\\ within\\ normal\\ limits\\.\ \(0\)\
\-\ ears\\:\\ no\\ external\\ lesions\\ or\\ deformities\\.\\ tm\\ pearly\\ grey\\,\\ and\\ regular\\ landmarks\\ visualized\\.\ \(0\)\
\-\ nose\\:\\ nares\\ patent\\.\\ sinuses\\ non\\-tender\\.\\ mucosal\\ membranes\\ pink\\ and\\ non\\-edematous\\.\ \(0\)\
\-\ mouth\\ \\/\\ throat\\:\\ regular\\ oral\\ mucosa\\,\\ non\\-erythematous\\ and\\ non\\-edematous\\.\\ no\\ lesions\\ or\\ ulcers\\.\\ normal\\ dentition\\.\ \(0\)\
\-\ neck\\:\\ normal\\ rom\\.\\ trachea\\ midline\\.\\ carotids\\ 2\\+\\.\\ thyroid\\ non\\-tender\\,\\ non\\-enlarged\\,\\ and\\ without\\ nodules\\.\\ no\\ lymph\\ node\\ prominence\\ appreciated\\.\\ \ \(0\)\
\-\ lungs\\:\\ equal\\ and\\ bl\\ breath\\ sounds\\.\\ normal\\ expansion\\.\\ no\\ rales\\,\\ rubs\\,\\ rhonchi\\,\\ or\\ wheeze\\ auscultated\\.\\ \ \(0\)\
\-\ heart\\:\\ pmi\\ regular\\.\\ regular\\ rate\\ and\\ rhythm\\.\\ s1\\ and\\ s2\\ appreciated\\.\\ no\\ murmurs\\,\\ gallops\\,\\ or\\ rubs\\.\\ peripheral\\ pulses\\ 2\\+\\.\ \(0\)\
\-\ abdomen\\:\\ regular\\ inspection\\.\\ bowel\\ sounds\\ heard\\ in\\ all\\ four\\ quadrants\\.\\ regular\\ liver\\ span\\.\\ non\\-tender\\.\\ \ \(0\)\
\-\ musculoskeletal\\:\\ regular\\ stability\\.\\ non\\-edematous\\ joints\\ with\\ normal\\ rom\\.\\ muscle\\ tone\\ regular\\.\\ \ \(0\)\
\-\ muscle\\ strength\\:\\ 5\\/5\\ throughout\ \(0\)\
\-\ neurologic\\:\ \(0\)\
\-\ cn\\ ii\\-xii\\ within\\ normal\\ limits\\.\\ reflexes\\ 4\\/4\\ bilaterally\\ throughout\\.\\ sensation\\ intact\\ to\\ light\\ touch\\,\\ and\\ pin\\ prick\\ on\\ upper\\ and\\ lower\\ extremities\\ bilaterally\\.\\ negative\\ babinski\\ reflex\\.\\ normal\\ gait\\.\\ \ \(0\)\
\-\ laboratory\\ data\\:\ \(0\)\
\-\ 03\\/19\\/13\\ \\-\\ 03\\/23\\/13\\ \\(initial\\ hospitalization\\)\ \(0\)\
\-\ cbc\\:\\ 03\\/19\\/13\\ plt\\ 6\ \(0\)\
\-\ cmp\\:\\ 03\\/19\\ \\-\\ 03\\/23\\ normal\\ gfr\ \(0\)\
\-\ immunology\\:\\ 03\\/20\\/13\\ ana\\ pos\\,\\ ssa\\ \\(ro\\)\\ h\\,\\ sm\\ \\(smith\\)\\ h\\,\\ ds\\-dna\\ h\\,\\ histone\\ ab\\ h\ \(0\)\
\-\ ua\\:\\ 3\\/21\\/13\\ negative\\ findings\ \(0\)\
\-\ 07\\/10\\/2017\\ \\(rheumatology\\ routine\\ labs\\)\ \(0\)\
\-\ urine\\ protein\\ creatinine\\ mass\\ ratio\\-\\ protein\\ total\\ random\\ urine\\-\\ high\\ 48\\,\\ protein\\/creatinine\\ ratio\\ high\\ 552\ \(0\)\
\-\ ua\\-\\ \\ hemoglobin\\ 2\\+\\,\\ protein\\ 2\\+\\ \ \(0\)\
\-\ 09\\/12\\/2017\\-\\ c3\\ serum\\ wnl\\,\\ and\\ c4\\ serum\\ high\ \(0\)\
\-\ 08\\/30\\/2017\ \(2\)\
\-\ renal\\ biopsy\\ report\\:\ \(0\)\
\-\ microscopic\\:\\ 3\\ core\\ bx\\ or\\ renal\\ cortex\\,\\ 2\\ cores\\ include\\ the\\ renal\\ capsule\\.\\ glomeruli\\-\\ 4\\/13\\ globally\\ sclerotic\\ \\(13\\%\\)\\,\\ normal\\ or\\ mildly\\ increased\\ in\\ size\\,\\ diffuse\\ mild\\-moderate\\ global\\ or\\ segmental\\ pas\\ positive\\ mesangial\\ expansion\\,\\ segmental\\ mild\\ mesangial\\ proliferation\\ in\\ 3\\ glomeruli\\,\\ cellular\\ crescents\\ in\\ 2\\ glomeruli\\,\\ fibrocellular\\ crescents\\ in\\ 3\\,\\ and\\ segmental\\ necrosis\\ without\\ crescent\\ formation\\ in\\ 1\\ glomerulus\\,\\ fibrous\\ crescent\\ in\\ 1\\ glomerulus\\.\\ tubulointerstitium\\-\\ well\\ circumscribed\\ zones\\ of\\ inflammation\\ with\\ lymphocytes\\,\\ plasma\\ cells\\,\\ and\\ rare\\ eosinophils\\ involving\\ estimated\\ 5\\-10\\ \\%\\ of\\ cortex\\,\\ foci\\ of\\ interstitial\\ pmn\\‚\\Ä\\ôs\\ adjacent\\ to\\ active\\ crescents\\,\\ interstitial\\ fibrosis\\ and\\ tubular\\ atrophy\\ in\\ 10\\-25\\%\\ cortex\\.\\ blood\\ vessels\\-\\ 3\\ small\\ interlobular\\ arteries\\ and\\ visible\\ periglomerular\\ arterioles\\ without\\ dx\\ pathological\\ changes\\.\ \(0\)\
\-\ immunofluorescence\\:\\ 10\\ glomeruli\\,\\ zero\\ \\%\\ globally\\ sclerotic\\;\\ iga\\ 1\\+\\ focal\\ segmental\\ granular\\ paramesangial\\/mesangial\\,\\ positive\\ epithelial\\ cells\\,\\ positive\\ protein\\ granules\\ and\\ casts\\;\\ igg\\ 1\\+\\ focal\\ segmental\\ granular\\ paramesangial\\/mesangial\\,\\ positive\\ protein\\ granules\\ and\\ casts\\,\\ positive\\ nuclear\\;\\ igm\\ 1\\+\\ granular\\ paramesangial\\/mesangial\\ and\\ segmental\\ capillary\\;\\ kappa\\ glomeruli\\ negative\\,\\ positive\\ casts\\;\\ lambda\\ glomeruli\\ negative\\,\\ positive\\ casts\\;\\ c1q\\ 1\\+\\ granular\\ paramesangial\\/mesangial\\;\\ c3\\ 1\\+\\ granular\\ paramesangial\\/mesangial\\;\\ albumin\\ and\\ fibrinogen\\ 1\\+\\ focal\\ segmental\\ glomerular\\ in\\ 3\\/10\\ glomeruli\\.\ \(0\)\
\-\ em\\:\\ 1\\ glomerulus\\.\\ mesangial\\ expansion\\ with\\ numerous\\ sized\\ electron\\ dense\\ deposits\\,\\ mesangial\\/paramesangial\\,\\ and\\ focal\\ subepithelial\\;\\ endocapillary\\ inflammatory\\ cells\\,\\ tubuloredicular\\ inclusions\\ in\\ glomerular\\ and\\ peritubular\\ capillary\\ endothelium\\;\\ epithelial\\ foot\\ process\\ simplification\\/effacement\\ with\\ incomplete\\ involvement\\ of\\ most\\ capillaries\\,\\ overall\\ involvement\\ estimated\\ 20\\-30\\%\\;\\ incomplete\\ loss\\ of\\ endothelial\\ fenestrations\\.\ \(0\)\
\-\ final\\ pathology\\ dx\\:\ \(0\)\
\-\ left\\ kidney\\-\\ percutaneous\\ needle\\ bx\ \(0\)\
\-\ active\\ and\\ sclerosing\\ immune\\ complex\\ gn\\ consistent\\ with\\ ln\\ isn\\/rps\\ class\\ 3\\ a\\/c\\;\\ cellular\\ crescents\\,\\ fibrocellular\\ crescents\\,\\ or\\ segmental\\ necrosis\\ are\\ identified\\ in\\ 20\\%\\ of\\ glomeruli\\.\ \(0\)\
\-\ comment\\-\\ unusual\\ features\\ include\\:\\ igm\\ dominant\\ fluorescence\\ and\\ presence\\ of\\ necrosis\\ and\\ crescent\\ formation\\ with\\ subendothelial\\ deposits\\.\\ these\\ features\\ taken\\ together\\ suggest\\ mechanism\\ of\\ autoimmune\\ injury\\ not\\ typical\\ of\\ ln\\.\ \(0\)\
\-\ patient\\ will\\ be\\ advised\\ to\\ continue\\ current\\ medication\\ regimen\\ of\\ mycophenolate\\ mofetil\\,\\ hydroxychloroquine\\ sulfate\\,\\ montelukast\\ sodium\\,\\ and\\ belimumab\\ for\\ her\\ current\\ medical\\ conditions\\.\\ it\\ is\\ imperative\\ that\\ the\\ patient\\ continues\\ with\\ her\\ immunosuppressive\\ therapy\\ of\\ mycophenolate\\ mofetil\\ to\\ adequately\\ treat\\ her\\ focal\\ lupus\\ nephritis\\ isn\\/rps\\ class\\ iii\\ a\\/c\\ and\\ prevent\\ relapse\\ with\\ recurrence\\ of\\ renal\\ inflammation\\ and\\ damage\\.\\ patient\\ will\\ be\\ advised\\ to\\ continue\\ hydroxychloroquine\\ sulfate\\ and\\ belimumab\\ medications\\ as\\ these\\ will\\ help\\ control\\ much\\ of\\ the\\ other\\ clinical\\ ailments\\ associated\\ with\\ sle\\ and\\ its\\ effects\\ on\\ multiple\\ organ\\ systems\\.\\ patient\\ has\\ noted\\ increased\\ asthma\\ symptoms\\ and\\ will\\ be\\ advised\\ to\\ continue\\ montelukast\\ sodium\\ as\\ prescribed\\ previously\\.\\ patient\\ is\\ now\\ in\\ the\\ maintenance\\ phase\\ of\\ therapy\\ for\\ her\\ focal\\ lupus\\ nephritis\\ and\\ will\\ be\\ advised\\ to\\ follow\\ up\\ every\\ 3\\ months\\ with\\ her\\ nephrologist\\ where\\ evaluation\\ to\\ monitor\\ ln\\ progression\\ will\\ consist\\ of\\ physical\\ exam\\,\\ urine\\ protein\\,\\ ua\\,\\ serum\\ c3\\ \\/\\ c4\\ \\/\\ anti\\-dna\\ levels\\,\\ cbc\\,\\ and\\ lft\\‚\\Ä\\ôs\\ will\\ ensue\\.\ \(0\)\
\-\ renal\\ ultrasound\ \(12\)\
\-\ clinical\\ indication\\:\\ \\ patient\\ with\\ hematuria\\,\\ microhematuria\\.\\ \\ icd\\-10\\ code\\ r31\\.9\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ real\\-time\\ renal\\ sonogram\\ was\\ performed\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ the\\ kidneys\\ appear\\ within\\ normal\\ limits\\ bilaterally\\.\\ there\\ are\\ no\\ renal\\ masses\\,\\ calculi\\ or\\ hydronephrosis\\.\\ there\\ are\\ no\\ perirenal\\ fluid\\ collections\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ right\\ kidney\\:\\ \\ measures\\ 12\\.7\\ x\\ 7\\.0\\ x\\ 5\\.0\\ cm\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ left\\ kidney\\:\\ \\ measures\\ 13\\.5\\ x\\ 5\\.1\\ x\\ 5\\.5\\ cm\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ there\\ is\\ no\\ aneurysmal\\ dilatation\\ of\\ the\\ abdominal\\ aorta\\ as\\ visualized\\.\\ the\\ inferior\\ vena\\ cava\\ is\\ unremarkable\\ as\\ visualized\\.\\ the\\ urinary\\ bladder\\ is\\ unremarkable\\ as\\ visualized\\.\\ the\\ ureteral\\ jets\\ were\\ demonstrated\\ bilaterally\\.\ \(0\)\
\-\ impression\\:\\ \\ unremarkable\\ renal\\ sonogram\\.\ \(0\)\
\-\ normal\\ renal\\ us\\ imaging\\ findings\\ of\\ the\\ right\\ kidney\\ will\\ be\\ discussed\\ with\\ patients\\ attached\\ images\\.\ \(0\)\
\-\ figure\\ titles\\ are\\ as\\ follows\\:\ \(0\)\
\-\ figure1\\.\\ 35\\ year\\-old\\ female\\ renal\\ us\\ \\(microhematuria\\)\ \(0\)\
\-\ figure\\ 2\\.\\ sagittal\\ us\\ midline\\ \\(inferior\\ vena\\ cava\\)\\ \ \(0\)\
\-\ figure\\ 3\\.\\ sagittal\\ midline\\ \\(aorta\\)\ \(0\)\
\-\ figure\\ 4\\.\\ transverse\\ midline\\ \\(aorta\\)\ \(0\)\
\-\ figure\\ 5\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 6\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 7\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 8\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 9\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(lateral\\ to\\ medial\\)\ \(0\)\
\-\ figure\\ 10\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(superior\\ to\\ inferior\\)\ \(0\)\
\-\ figure\\ 11\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(superior\\ to\\ inferior\\)\ \(0\)\
\-\ figure\\ 12\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(superior\\ to\\ inferior\\)\ \(0\)\
\-\ figure\\ 13\\.\\ left\\ lateral\\ decubitus\\ transverse\\ right\\ kidney\\ \\(middle\\)\ \(0\)\
\-\ figure\\ 14\\.\\ left\\ lateral\\ decubitus\\ sagittal\\ right\\ kidney\\ \\(middle\\)\ \(0\)\
\-\ figure\\ 15\\.\\ transverse\\ bladder\ \(0\)\
\-\ figure\\ 16\\.\\ transverse\\ bladder\\ \\(right\\ jet\\)\ \(0\)\
\-\ see\\ captions\\ attached\\ to\\ each\\ figure\\ for\\ further\\ description\\.\ \(0\)\
\-\ sclerosing\\ immune\\ complex\\ glomerulonephritis\\ consistent\\ with\\ focal\\ lupus\\ nephritis\\ isn\\/rps\\ class\\ iii\\ a\\/c\ \(0\)\
\-\ 1\\)\\ focal\\ lupus\\ nephritis\ \(0\)\
\-\ 2\\)\\ c3\\ glomerulonephritis\ \(0\)\
\-\ 3\\)\\ post\\ streptococcal\\ glomerulonephritis\\ \ \(0\)\
\-\ 4\\)\\ iga\\ nephropthy\ \(0\)\
\-\ patient\\ is\\ a\\ 35\\-year\\-old\\ african\\ american\\ female\\ g1p1\\ with\\ a\\ previous\\ pmh\\ of\\ asthma\\ and\\ atopic\\ dermatitis\\ who\\ 4\\ years\\ ago\\ \\(3\\/19\\/2013\\)\\ initially\\ presented\\ to\\ the\\ ed\\ due\\ to\\ acute\\ onset\\ of\\ \\‚\\Ä\\údark\\ blueish\\ \\/\\ purple\\ spots\\ on\\ the\\ inside\\ of\\ her\\ mouth\\ and\\ red\\ bruises\\ on\\ her\\ arms\\‚\\Ä\\ù\\ with\\ no\\ recent\\ history\\ of\\ trauma\\ or\\ illness\\.\\ she\\ notes\\ that\\ while\\ in\\ the\\ ed\\ she\\ further\\ developed\\ \\‚\\Ä\\úpetechiae\\‚\\Ä\\ù\\ on\\ her\\ arms\\ and\\ legs\\.\\ patient\\‚\\Ä\\ôs\\ initial\\ lab\\ results\\ showed\\ thrombocytopenia\\ and\\ normocytic\\ anemia\\.\\ upon\\ further\\ workup\\ and\\ hospitalization\\ consisting\\ of\\ multiple\\ blood\\ transfusions\\ the\\ patient\\ was\\ diagnosed\\ with\\ itp\\ \\(idiopathic\\ thrombocytopenia\\ purpura\\ and\\ sle\\ \\ \\(systemic\\ lupus\\ erythematosus\\)\\.\\ she\\ was\\ started\\ on\\ a\\ tapered\\ course\\ of\\ prednisone\\ and\\ hydroxychloroquine\\ sulfate\\ and\\ later\\ followed\\ up\\ with\\ hematology\\ and\\ rheumatology\\.\\ \ \(0\)\
\-\ six\\ months\\ later\\ patient\\ experienced\\ a\\ 2\\ month\\ history\\ of\\ 2\\-6\\ \\/10\\ crampy\\,\\ non\\-radiating\\,\\ lower\\ back\\ \\/\\ buttocks\\ \\/\\ abdominal\\ pain\\,\\ which\\ upon\\ further\\ us\\ and\\ ct\\ imaging\\ and\\ eventual\\ surgery\\ found\\ to\\ be\\ due\\ to\\ a\\ mature\\ cystic\\ teratoma\\.\\ patient\\ underwent\\ left\\ oophorectomy\\ during\\ surgery\\.\\ of\\ note\\,\\ patient\\ also\\ has\\ had\\ hysterectomy\\ due\\ to\\ uterine\\ fibroids\\.\\ otherwise\\,\\ until\\ 07\\/10\\/2017\\ \\(4\\ years\\ after\\ dx\\ of\\ sle\\ and\\ itp\\)\\ patient\\‚\\Ä\\ôs\\ chronic\\ conditions\\ had\\ been\\ well\\ managed\\ with\\ hydroxychloroquine\\,\\ and\\ montelukast\\.\ \(0\)\
\-\ patient\\ states\\ that\\ after\\ routine\\ follow\\ up\\ with\\ her\\ rheumatologist\\ on\\ 07\\/10\\/2017\\ there\\ were\\ ua\\ findings\\ of\\ hematuria\\ and\\ proteinuria\\ \\(555\\ \\-\\ 650\\)\\ in\\ the\\ patient\\‚\\Ä\\ôs\\ urine\\.\\ she\\ was\\ referred\\ to\\ a\\ nephrologist\\ where\\ further\\ evaluation\\ through\\ us\\ imaging\\ and\\ biopsy\\ were\\ performed\\ on\\ 08\\/30\\/2017\\.\\ renal\\ biopsy\\ showed\\ new\\ diagnosis\\ of\\ glomerular\\ kidney\\ disease\\,\\ active\\ and\\ sclerosing\\ immune\\ complex\\ gn\\ consistent\\ with\\ ln\\ isn\\/rps\\ class\\ 3\\ a\\/c\\ \\.\\ patient\\ was\\ started\\ on\\ mycophenolate\\ mofetil\\ in\\ addition\\ to\\ her\\ previous\\ medications\\,\\ and\\ also\\ notes\\ a\\ course\\ of\\ tapered\\ prednisone\\.\\ patient\\ also\\ notes\\ that\\ she\\ had\\ begun\\ a\\ new\\ sle\\ medication\\,\\ belimumab\\,\\ during\\ late\\ august\\ 2017\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ review\\ of\\ systems\\:\ \(0\)\
\-\ patient\\ reports\\ fatigue\\,\\ photosensitivity\\,\\ photophobia\\,\\ heat\\ intolerance\\ \\(resulting\\ in\\ ha\\ and\\ nausea\\)\\,\\ and\\ painful\\ joints\\ \\(bl\\ knees\\ and\\ elbows\\)\\.\\ she\\ denies\\ fever\\,\\ loss\\ of\\ appetite\\,\\ dizziness\\,\\ insomnia\\,\\ weight\\ loss\\,\\ chills\\,\\ night\\ sweats\\,\\ chest\\ pain\\,\\ sob\\,\\ abdominal\\ pain\\,\\ urinary\\ frequency\\ \\/\\ urgency\\ \\/\\ pain\\,\\ constipation\\,\\ diarrhea\\,\\ weakness\\,\\ bruising\\,\\ bleeding\\,\\ weakness\\,\\ or\\ gross\\ neurologic\\ deficits\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ past\\ medical\\ history\\:\ \(0\)\
\-\ asthma\\,\\ atopic\\ dermatitis\\,\\ sle\\,\\ itp\\,\\ mature\\ cystic\\ teratoma\ \(0\)\
\-\ surgical\\ history\\:\ \(1\)\
\-\ hysterectomy\\,\\ left\\ oophorectomy\ \(0\)\
\-\ family\\ history\\:\ \(0\)\
\-\ maternal\\-\\ htn\\,\\ type\\ 2\\ dm\ \(0\)\
\-\ paternal\\-\\ sle\\,\\ breast\\ carcinoma\ \(0\)\
\-\ allergies\\:\ \(0\)\
\-\ reports\\ seafood\\,\\ tetanus\ \(0\)\
\-\ social\\ history\\:\ \(0\)\
\-\ works\\ in\\ medical\\ office\\,\\ and\\ lives\\ at\\ home\\ with\\ daughter\\.\\ never\\ a\\ smoker\\.\\ denies\\ ever\\ using\\ illicit\\ drugs\\.\\ \ \(0\)\
\-\ alcohol\\ use\\ of\\ 2\\-3\\ times\\ per\\ month\\.\ \(0\)\
\-\ medications\\:\ \(0\)\
\-\ mycophenolate\\ mofetil\\,\\ hydroxychloroquine\\ sulfate\\,\\ montelukast\\ sodium\\,\\ and\\ belimumab\\.\ \(0\)\
\-\ kidney\\ disease\\ is\\ often\\ referred\\ to\\ as\\ the\\ \\‚\\Ä\\úsilent\\ illness\\,\\‚\\Ä\\ù\\ as\\ often\\ patients\\ are\\ asymptomatic\\ in\\ the\\ earlier\\ stages\\,\\ and\\ by\\ the\\ time\\ they\\ do\\ become\\ symptomatic\\ they\\ already\\ have\\ severely\\ advanced\\ renal\\ disease\\.\\ due\\ to\\ this\\ renal\\ disease\\ plays\\ a\\ large\\ role\\ in\\ overall\\ morbidity\\ and\\ mortality\\,\\ and\\ throughout\\ the\\ past\\ few\\ decades\\ has\\ become\\ a\\ major\\ public\\ health\\ concern\\.\\ recent\\ statistics\\ from\\ the\\ nih\\ have\\ shown\\ that\\ renal\\ disease\\ is\\ responsible\\ for\\ more\\ deaths\\ in\\ a\\ year\\ than\\ breast\\ and\\ prostate\\ cancer\\ combined\\,\\ and\\ accounts\\ for\\ approximately\\ 50\\ billion\\ dollars\\ in\\ medicaid\\ spending\\ per\\ year\\ \\[1\\-3\\]\\.\\ although\\ the\\ incidence\\ of\\ the\\ disease\\ has\\ stabilized\\ over\\ the\\ past\\ few\\ years\\ it\\ still\\ has\\ a\\ substantial\\ prevalence\\ at\\ 14\\%\\ of\\ the\\ general\\ population\\,\\ which\\ is\\ why\\ awareness\\ for\\ disease\\ and\\ prevention\\ and\\ proactive\\ efforts\\ for\\ diagnosis\\ is\\ important\\.\\ it\\ is\\ important\\ to\\ first\\ understand\\ that\\ renal\\ disease\\ consists\\ of\\ a\\ wide\\ variety\\ of\\ disorders\\ \\(glomerular\\ disease\\,\\ tubular\\ disease\\,\\ vascular\\ disease\\ ect\\.\\)\\.\\ for\\ this\\ discussion\\ we\\ will\\ focus\\ on\\ glomerular\\ disease\\ \\(consisting\\ of\\ nephritic\\ and\\ nephrotic\\ conditions\\)\\,\\ specifically\\ focusing\\ on\\ lupus\\ nephritis\\ \\(ln\\)\\ and\\ c3\\ glomerulonephritis\\ \\(c3gn\\)\\ and\\ how\\ these\\ conditions\\ manifested\\ in\\ our\\ patient\\.\\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ what\\ is\\ interesting\\ about\\ our\\ patient\\'s\\ case\\ is\\ that\\ she\\ initially\\ presented\\ with\\ dark\\ blueish\\ \\/\\ purple\\ spots\\ on\\ the\\ inside\\ of\\ her\\ mouth\\ and\\ red\\ bruises\\ on\\ her\\ arms\\,\\ which\\ was\\ later\\ diagnosed\\ during\\ her\\ hospital\\ visit\\ as\\ itp\\ \\(immune\\ thrombocytopenic\\ purpura\\)\\.\\ primary\\ itp\\ is\\ an\\ autoimmune\\ process\\ in\\ which\\ auto\\-antibodies\\ are\\ produced\\ against\\ the\\ hosts\\ platelets\\.\\ these\\ antibodies\\ coat\\ host\\ platelets\\ and\\ damage\\ them\\ resulting\\ in\\ their\\ removal\\ by\\ the\\ spleen\\ resulting\\ in\\ thrombocytopenia\\ and\\ increased\\ bleeding\\ risk\\.\\ around\\ that\\ same\\ time\\ laboratory\\ findings\\ also\\ were\\ significant\\ for\\ a\\ diagnosis\\ of\\ sle\\ \\(systemic\\ lupus\\ erythematosus\\)\\.\\ traditionally\\ primary\\ itp\\ is\\ a\\ diagnosis\\ of\\ exclusion\\ if\\ there\\ is\\ only\\ findings\\ of\\ thrombocytopenia\\ without\\ any\\ other\\ findings\\ indicative\\ of\\ another\\ etiology\\.\\ with\\ this\\ being\\ said\\,\\ it\\ appears\\ that\\ our\\ patient\\ had\\ a\\ secondary\\ diagnosis\\ of\\ \\[sle\\]\\ associated\\ with\\ \\ itp\\.\\ the\\ diagnosis\\ of\\ sle\\ with\\ the\\ itp\\ co\\-morbidity\\ has\\ been\\ shown\\ to\\ be\\ rare\\ as\\ in\\ a\\ \\ recent\\ study\\ of\\ 152\\ patients\\ diagnosed\\ with\\ sle\\ there\\ was\\ reclassification\\ of\\ 12\\ individuals\\ having\\ secondary\\ itp\\ \\(8\\ percent\\)\\ during\\ the\\ two\\ years\\ of\\ evaluation\\ \\[4\\]\\.\\ although\\ the\\ patient\\ at\\ the\\ time\\ of\\ the\\ \\[sle\\]\\ associated\\ itp\\ diagnosis\\ had\\ no\\ laboratory\\ evidence\\ of\\ renal\\ disease\\,\\ the\\ likelihood\\ of\\ the\\ patient\\ to\\ develop\\ kidney\\ disease\\ in\\ the\\ future\\ has\\ been\\ reported\\ as\\ 50\\%\\ just\\ with\\ only\\ the\\ singular\\ diagnosis\\ of\\ sle\\.\\ no\\ studies\\ with\\ significant\\ data\\ could\\ be\\ found\\ to\\ support\\ increased\\ risk\\ of\\ renal\\ disease\\ with\\ both\\ sle\\ and\\ itp\\ diagnosis\\.\ \(0\)\
\-\ as\\ stated\\ previously\\,\\ it\\ is\\ important\\ for\\ those\\ at\\ risk\\ for\\ renal\\ disease\\ to\\ be\\ advised\\ about\\ preventative\\ measures\\,\\ proactive\\ screening\\ and\\ diagnostic\\ procedures\\ to\\ diagnose\\ renal\\ disease\\ in\\ its\\ earliest\\ stages\\ even\\ when\\ its\\ is\\ asymptomatic\\.\\ in\\ our\\ patient\\‚\\Ä\\ôs\\ case\\,\\ regular\\ follow\\ up\\ and\\ screening\\ with\\ her\\ rheumatologist\\ helped\\ identify\\ early\\ urinary\\ irregularities\\ \\(microhematuria\\ and\\ proteinuria\\ with\\ normal\\ gfr\\)\\.\\ this\\ allowed\\ for\\ further\\ evaluation\\ resulting\\ in\\ diagnosis\\.\\ the\\ evaluation\\ algorithm\\ for\\ hematuria\\ and\\ proteinuria\\ begins\\ with\\ serologic\\ testing\\,\\ then\\ imaging\\ \\(renal\\ us\\,\\ ct\\,\\ or\\ ivp\\)\\,\\ and\\ finally\\ biopsy\\,\\ \\(if\\ the\\ diagnosis\\ was\\ not\\ made\\ from\\ prior\\ studies\\)\\.\\ in\\ this\\ patient\\‚\\Ä\\ôs\\ case\\ serologic\\ testing\\ showed\\ supportive\\ findings\\ for\\ sle\\,\\ but\\ imaging\\ was\\ needed\\ to\\ rule\\ out\\ any\\ other\\ possible\\ diagnosis\\.\\ renal\\ us\\ was\\ performed\\ without\\ any\\ pathological\\ findings\\.\\ at\\ this\\ time\\ there\\ are\\ no\\ imaging\\ studies\\ that\\ can\\ accurately\\ diagnose\\ glomerular\\ disease\\.\\ a\\ renal\\ biopsy\\ was\\ needed\\ to\\ be\\ performed\\ for\\ not\\ only\\ a\\ clear\\ diagnosis\\,\\ but\\ also\\ the\\ fact\\ that\\ specific\\ diagnosis\\ and\\ classification\\ aids\\ in\\ therapeutic\\ decision\\ making\\ for\\ glomerular\\ disease\\.\\ prior\\ to\\ biopsy\\ a\\ plausible\\ nephritic\\ syndrome\\ \\(proteinuria\\ \\<\\ 3\\.5\\ g\\ per\\ day\\ or\\ 2\\+\\ or\\ less\\ on\\ urine\\ dipstick\\ analysis\\)\\ differential\\ diagnosis\\ consisted\\ of\\ \\ lupus\\ nephritis\\ \\(especially\\ in\\ the\\ context\\ of\\ a\\ sle\\ diagnosis\\)\\,\\ c3\\ glomerulonephritis\\ \\(a\\ rare\\ form\\ of\\ mpgn\\ but\\ not\\ out\\ of\\ reach\\ considering\\ the\\ laboratory\\ findings\\ and\\ possible\\ preceding\\ uri\\)\\,\\ post\\ streptococcal\\ glomerulonephritis\\ \\(considering\\ labs\\ and\\ possibility\\ of\\ preceding\\ uri\\)\\,\\ and\\ iga\\ nephropathy\\.\\ \ \(0\)\
\-\ it\\ was\\ not\\ surprising\\ that\\ the\\ biopsy\\ findings\\ were\\ indicative\\ of\\ lupus\\ nephritis\\ \\(specifically\\ \\-\\ sclerosing\\ immune\\ complex\\ glomerulonephritis\\ class\\ iii\\ a\\/c\\)\\.\\ the\\ following\\ findings\\ were\\ indicative\\ of\\ this\\ diagnosis\\:\\ glomeruli\\ 4\\/13\\ globally\\ sclerotic\\ \\(13\\%\\)\\ which\\ is\\ less\\ than\\ the\\ 50\\%\\ glomeruli\\ involvement\\ limit\\ on\\ lm\\;\\ \\ mesangial\\ expansion\\ with\\ numerous\\ sized\\ electron\\ dense\\ deposits\\ and\\ inclusions\\ in\\ glomerular\\ and\\ peritubular\\ capillary\\ endothelium\\ on\\ em\\;\\ and\\ class\\ a\\/c\\ findings\\ of\\ active\\ and\\ chronic\\ sclerosing\\ lesions\\.\\ \\ \ \(0\)\
\-\ ln\\ class\\ iii\\ a\\/c\\ description\\:\ \(0\)\
\-\ focal\\ lupus\\ nephritis\\ \\(class\\ iii\\)\\ \\-\\ hematuria\\ and\\ proteinuria\\ are\\ present\\,\\ with\\ possible\\ hypertension\\ decreased\\ gfr\\ and\\/or\\ nephrotic\\ syndrome\\.\\ histologic\\ findings\\ of\\ 50\\ percent\\ or\\ less\\ of\\ glomeruli\\ affected\\ on\\ light\\ microscopy\\,\\ im\\ shows\\ all\\ glomeruli\\ affected\\,\\ em\\ shows\\ mesangium\\ and\\ capillary\\ wall\\ subendothelial\\ deposits\\ \\[42\\]\\.\\ further\\ subclass\\ categories\\ of\\ class\\ iii\\ are\\ as\\ follows\\:\\ 1\\.\\ class\\ iii\\ \\(a\\)\\,\\ active\\ lesions\\,\\ focal\\ proliferative\\ lupus\\ nephritis\\ 2\\.\\ class\\ iii\\ \\(a\\/c\\)\\,\\ active\\ and\\ chronic\\ lesions\\,\\ focal\\ proliferative\\ and\\ sclerosing\\ lupus\\ nephritis\\ 3\\.class\\ iii\\ \\(c\\)\\,\\ chronic\\ inactive\\ lesions\\ with\\ scarring\\,\\ focal\\ sclerosing\\ lupus\\ nephritis\\ \\[7\\]\\.\\ \ \(0\)\
\-\ this\\ case\\ was\\ not\\ completely\\ straightforward\\ as\\ there\\ were\\ unusual\\ features\\ which\\ \\ include\\:\\ igm\\ dominant\\ fluorescence\\ and\\ presence\\ of\\ necrosis\\ and\\ crescent\\ formation\\ with\\ subendothelial\\ deposits\\;\\ these\\ features\\ taken\\ together\\ suggest\\ mechanism\\ of\\ autoimmune\\ injury\\ not\\ typical\\ of\\ ln\\.\\ c3gn\\ is\\ a\\ subclass\\ of\\ mpgn\\ which\\ has\\ em\\ findings\\ of\\ subendothelial\\ and\\ mesangial\\ electron\\-dense\\ deposits\\ possibly\\ similar\\ to\\ what\\ is\\ seen\\ in\\ addition\\ to\\ the\\ ln\\ findings\\ \\[5\\,6\\]\\.\\ if\\ this\\ is\\ the\\ case\\ the\\ question\\ is\\ how\\ does\\ this\\ affect\\ overall\\ management\\?\\ surprisingly\\,\\ the\\ recommended\\ non\\-immunosuppressive\\ agents\\ \\(acei\\,\\ arb\\,\\ and\\ lipid\\ lowering\\ agents\\)\\ and\\ immunosuppressives\\ are\\ the\\ same\\.\\ there\\ has\\ been\\ some\\ debate\\ about\\ the\\ effectiveness\\ of\\ immunosuppressive\\ therapy\\,\\ but\\ in\\ a\\ recent\\ retrospective\\ cohort\\ study\\ of\\ 60\\ c3gn\\ patients\\ the\\ immunotherapy\\ combination\\ of\\ mycophenolate\\ mofetil\\ and\\ glucocorticoids\\ was\\ found\\ to\\ be\\ therapeutically\\ effective\\ in\\ c3gn\\ \\[8\\]\\.\\ immunosuppressive\\ therapy\\ consists\\ of\\ aggressive\\ induction\\ and\\ less\\ aggressive\\ maintenance\\ phases\\.\\ patient\\ is\\ in\\ maintenance\\ phase\\ with\\ stable\\ disease\\ and\\ currently\\ following\\ up\\ with\\ the\\ nephrologist\\ every\\ few\\ months\\ for\\ routine\\ examination\\.\\ \ \(0\)\
\-\ the\\ prognosis\\ of\\ either\\ ln\\ or\\ c3gn\\ varies\\ amongst\\ patients\\,\\ but\\ both\\ carry\\ the\\ risk\\ of\\ renal\\ disease\\ progression\\ to\\ esrd\\.\\ reassuringly\\,\\ what\\ has\\ been\\ noted\\ in\\ both\\ diseases\\ is\\ that\\ early\\ administration\\ of\\ non\\-immunosuppressive\\ and\\ immunosuppressive\\ therapies\\ have\\ greatly\\ reduced\\ the\\ rate\\ of\\ progression\\ to\\ esrd\\.\\ interestingly\\,\\ there\\ were\\ not\\ many\\ records\\ or\\ studies\\ of\\ patients\\ with\\ both\\ ln\\ and\\ c3gn\\ documented\\.\\ possible\\ further\\ investigation\\ should\\ be\\ performed\\ into\\ the\\ incidence\\ of\\ having\\ both\\ ln\\ and\\ c3gn\\ disease\\ and\\ its\\ associated\\ variety\\ of\\ clinical\\ symptoms\\,\\ risk\\ factors\\,\\ and\\ prognosis\\ would\\ be\\ informative\\.\\ \\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ xu\\ jq\\,\\ murphy\\ sl\\,\\ kochanek\\ kd\\,\\ bastian\\ ba\\.\\ deaths\\:\\ final\\ data\\ for\\ 2013\\.\\ www\\.cdc\\.gov\\ \\.\\ published\\ february\\ 16\\,\\ 2016\\.\\ accessed\\ december\\ 6\\,\\ 2016\\.\\ \ \(0\)\
\-\ 2\\.\\ centers\\ for\\ disease\\ control\\ and\\ prevention\\.\\ age\\-adjusted\\ prevalence\\ of\\ ckd\\ stages\\ 1\\-4\\ by\\ gender\\ 1999\\-2012\\.\\ chronic\\ kidney\\ disease\\ \\(ckd\\)\\ surveillance\\ project\\ website\\.\\ https\\:\\/\\/nccd\\.cdc\\.gov\\ \\.\\ accessed\\ december\\ 6\\,\\ 2016\\.\\ \ \(0\)\
\-\ 3\\.\\ centers\\ for\\ disease\\ control\\ and\\ prevention\\.\\ age\\-adjusted\\ prevalence\\ of\\ ckd\\ stages\\ 1\\-4\\ by\\ race\\/ethnicity\\ 1999\\-2012\\.\\ chronic\\ kidney\\ disease\\ \\(ckd\\)\\ surveillance\\ project\\ website\\.\\ https\\:\\/\\/nccd\\.cdc\\.gov\\ \\.\\ accessed\\ december\\ 6\\,\\ 2016\\.\ \(0\)\
\-\ 4\\.\\ portielje\\ je\\,\\ westendorp\\ rg\\,\\ kluin\\-nelemans\\ hc\\,\\ brand\\ a\\.\\ morbidity\\ and\\ mortality\\ in\\ adults\\ with\\ idiopathic\\ thrombocytopenic\\ purpura\\.\\ blood\\ 2001\\;\\ 97\\:2549\\.\ \(0\)\
\-\ 5\\.\\ fakhouri\\ f\\,\\ fr\\√\\©meaux\\-bacchi\\ v\\,\\ no\\√\\´l\\ lh\\,\\ et\\ al\\.\\ c3\\ glomerulopathy\\:\\ a\\ new\\ classification\\.\\ nat\\ rev\\ nephrol\\ 2010\\;\\ 6\\:494\\.\ \(0\)\
\-\ 6\\.\\ bomback\\ as\\,\\ appel\\ gb\\.\\ pathogenesis\\ of\\ the\\ c3\\ glomerulopathies\\ and\\ reclassification\\ of\\ mpgn\\.\\ nat\\ rev\\ nephrol\\ 2012\\;\\ 8\\:634\\.\ \(0\)\
\-\ 7\\.\\ smet\\ ad\\,\\ kuypers\\ d\\,\\ evenepoel\\ p\\,\\ et\\ al\\.\\ \\'full\\ house\\'\\ positive\\ immunohistochemical\\ membranoproliferative\\ glomerulonephritis\\ in\\ a\\ patient\\ with\\ portosystemic\\ shunt\\.\\ nephrol\\ dial\\ transplant\\ 2001\\;\\ 16\\:2258\\.\ \(0\)\
\-\ 8\\.\\ rabasco\\ c\\,\\ cavero\\ t\\,\\ rom\\√\\°n\\ e\\,\\ et\\ al\\.\\ effectiveness\\ of\\ mycophenolate\\ mofetil\\ in\\ c3\\ glomerulonephritis\\.\\ kidney\\ int\\ 2015\\;\\ 88\\:1153\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ glomeruli\\:\\ 0\\.02697647454029954\ \(0\)\
\-\ itp\\:\\ 0\\.02697647454029954\ \(0\)\
\-\ ln\\:\\ 0\\.025629821101534504\ \(0\)\
\-\ figure\\:\\ 0\\.024496359195121716\ \(0\)\
\-\ sle\\:\\ 0\\.023106641110788907\ \(0\)\
\-\ nephritis\\:\\ 0\\.022372236022087343\ \(0\)\
\-\ lupus\\:\\ 0\\.019748573149343925\ \(0\)\
\-\ a\\/c\\:\\ 0\\.019619254211126938\ \(0\)\
\-\ class\\:\\ 0\\.018864814700607135\ \(0\)\
\-\ c3gn\\:\\ 0\\.018631832417803588\ \(0\)\
\-\ glomerular\\:\\ 0\\.017944985659049777\ \(0\)\
\-\ renal\\:\\ 0\\.017829691315681035\ \(0\)\
\-\ decubitus\\:\\ 0\\.017571818086994283\ \(0\)\
\-\ kidney\\:\\ 0\\.01726971184962264\ \(0\)\
\-\ glomerulonephritis\\:\\ 0\\.01720274938635461\ \(0\)\
\-\ \\:\\:\\ 0\\.0160395278839255\ \(0\)\
\-\ mycophenolate\\:\\ 0\\.015970142072403076\ \(0\)\
\-\ mofetil\\:\\ 0\\.015970142072403076\ \(0\)\
\-\ c3\\:\\ 0\\.014712828919305278\ \(0\)\
\-\ \\,\\:\\ 0\\.013486461597328627\ \(0\)\
\-\ mesangial\\:\\ 0\\.013308451727002563\ \(0\)\
\-\ paramesangial\\/mesangial\\:\\ 0\\.013308451727002563\ \(0\)\
\-\ \\/\\:\\ 0\\.012742749317125327\ \(0\)\
\-\ crescents\\:\\ 0\\.012262033881954336\ \(0\)\
\-\ \\;\\:\\ 0\\.012230804278095373\ \(0\)\
\-\ regular\\:\\ 0\\.01189710477284223\ \(0\)\
\-\ \\)\\:\\ 0\\.011633766719238669\ \(0\)\
\-\ hydroxychloroquine\\:\\ 0\\.01121561603690611\ \(0\)\
\-\ \\(\\:\\ 0\\.011123323683102926\ \(0\)\
\-\ disease\\:\\ 0\\.010964727074760964\ \(0\)\
\-\ iii\\:\\ 0\\.010900808095742504\ \(0\)\
\-\ her\\:\\ 0\\.010861039619199606\ \(0\)\
\-\ segmental\\:\\ 0\\.010832814211787844\ \(0\)\
\-\ \\]\\:\\ 0\\.010801239135538198\ \(0\)\
\-\ \\[\\:\\ 0\\.01077007149100702\ \(0\)\
\-\ sclerosing\\:\\ 0\\.010682436038016468\ \(0\)\
\-\ isn\\/rps\\:\\ 0\\.010646761381602051\ \(0\)\
\-\ subendothelial\\:\\ 0\\.010646761381602051\ \(0\)\
\-\ belimumab\\:\\ 0\\.010646761381602051\ \(0\)\
\-\ 1\\+\\:\\ 0\\.01045470287362876\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0100717779659623\ \(0\)\
\-\ deposits\\:\\ 0\\.009999423112250307\ \(0\)\
\-\ montelukast\\:\\ 0\\.009809627105563469\ \(0\)\
\-\ proteinuria\\:\\ 0\\.00955708299241923\ \(0\)\
\-\ ckd\\:\\ 0\\.009319934946012546\ \(0\)\
\-\ immunosuppressive\\:\\ 0\\.008972492829524888\ \(0\)\
\-\ granular\\:\\ 0\\.008944967792980577\ \(0\)\
\-\ focal\\:\\ 0\\.008842368130936239\ \(0\)\
\-\ casts\\:\\ 0\\.008702995786874876\ \(0\)\
\-\ immune\\:\\ 0\\.008574915773003244\ \(0\)\
\-\ sulfate\\:\\ 0\\.008482800669973964\ \(0\)\
\-\ lateral\\:\\ 0\\.008363532815328579\ \(0\)\
\-\ findings\\:\\ 0\\.008237486122237136\ \(0\)\
\-\ sagittal\\:\\ 0\\.00823272138286565\ \(0\)\
\-\ advised\\:\\ 0\\.008124292299941655\ \(0\)\
\-\ bl\\:\\ 0\\.007993108510423041\ \(0\)\
\-\ em\\:\\ 0\\.007993108510423041\ \(0\)\
\-\ 07\\/10\\/2017\\:\\ 0\\.007985071036201538\ \(0\)\
\-\ glomerulus\\:\\ 0\\.007985071036201538\ \(0\)\
\-\ mpgn\\:\\ 0\\.007985071036201538\ \(0\)\
\-\ protein\\:\\ 0\\.007943300045513014\ \(0\)\
\-\ thrombocytopenia\\:\\ 0\\.007865861510836295\ \(0\)\
\-\ us\\:\\ 0\\.007575745365272759\ \(0\)\
\-\ crescent\\:\\ 0\\.007548996457131595\ \(0\)\
\-\ globally\\:\\ 0\\.007357220329172603\ \(0\)\
\-\ nephrologist\\:\\ 0\\.007357220329172603\ \(0\)\
\-\ will\\:\\ 0\\.007264894071682451\ \(0\)\
\-\ transverse\\:\\ 0\\.007241886128940211\ \(0\)\
\-\ non\\-edematous\\:\\ 0\\.00698995120950941\ \(0\)\
\-\ nephrol\\:\\ 0\\.00698995120950941\ \(0\)\
\-\ patient\\:\\ 0\\.0069830863933401195\ \(0\)\
\-\ positive\\:\\ 0\\.006697791280879509\ \(0\)\
\-\ 2\\+\\:\\ 0\\.006601550675537714\ \(0\)\
\-\ further\\:\\ 0\\.0065638747386479665\ \(0\)\
\-\ biopsy\\:\\ 0\\.0064075642184351815\ \(0\)\
\-\ stages\\:\\ 0\\.006191592958759132\ \(0\)\
\-\ gfr\\:\\ 0\\.00610151891511473\ \(0\)\
\-\ capillary\\:\\ 0\\.006076484045951977\ \(0\)\
\-\ or\\:\\ 0\\.00604784268697891\ \(0\)\
\-\ \\%\\:\\ 0\\.006018481380875627\ \(0\)\
\-\ iga\\:\\ 0\\.005994831382817281\ \(0\)\
\-\ active\\:\\ 0\\.005910432679429131\ \(0\)\
\-\ purpura\\:\\ 0\\.005899396133127221\ \(0\)\
\-\ as\\:\\ 0\\.005854064791187173\ \(0\)\
\-\ that\\:\\ 0\\.005793402618135478\ \(0\)\
\-\ igm\\:\\ 0\\.0056617473428486964\ \(0\)\
\-\ microhematuria\\:\\ 0\\.0056617473428486964\ \(0\)\
\-\ and\\:\\ 0\\.005652456701736328\ \(0\)\
\-\ in\\:\\ 0\\.005598272381090343\ \(0\)\
\-\ maintenance\\:\\ 0\\.005594620556477572\ \(0\)\
\-\ prevention\\:\\ 0\\.005532127013464029\ \(0\)\
\-\ h\\:\\ 0\\.005432403756558198\ \(0\)\
\-\ december\\:\\ 0\\.00541875460136801\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.005398003374854526\ \(0\)\
\-\ 03\\/19\\/13\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ 08\\/30\\/2017\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ 4\\/13\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ fibrocellular\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ peritubular\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ fluorescence\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ blueish\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ proactive\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ nephritic\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ reclassification\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ non\\-immunosuppressive\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ age\\-adjusted\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ 1999\\-2012\\.\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ \\/\\/nccd\\.cdc\\.gov\\:\\ 0\\.005323380690801026\ \(0\)\
\-\ s\\:\\ 0\\.005179762581461989\ \(0\)\
\-\ be\\:\\ 0\\.005172354288487645\ \(0\)\
\-\ to\\:\\ 0\\.005157827396654423\ \(0\)\
\-\ sodium\\:\\ 0\\.005144949463801947\ \(0\)\
\-\ conditions\\:\\ 0\\.00513426356581964\ \(0\)\
\-\ notes\\:\\ 0\\.005106399088422602\ \(0\)\
\-\ 2016\\:\\ 0\\.005106399088422602\ \(0\)\
\-\ expansion\\:\\ 0\\.005084961640070539\ \(0\)\
\-\ she\\:\\ 0\\.005069898245827055\ \(0\)\
\-\ dx\\:\\ 0\\.0050694226441107765\ \(0\)\
\-\ urine\\:\\ 0\\.004980882296784245\ \(0\)\
\-\ accessed\\:\\ 0\\.004966769849448636\ \(0\)\
\-\ autoimmune\\:\\ 0\\.004934984233677558\ \(0\)\
\-\ our\\:\\ 0\\.004905710426159581\ \(0\)\
\-\ inclusions\\:\\ 0\\.0049048135527817345\ \(0\)\
\-\ gn\\:\\ 0\\.0049048135527817345\ \(0\)\
\-\ atopic\\:\\ 0\\.0049048135527817345\ \(0\)\
\-\ subclass\\:\\ 0\\.0049048135527817345\ \(0\)\
\-\ hematuria\\:\\ 0\\.004895343585952587\ \(0\)\
\-\ normal\\:\\ 0\\.004853668313764859\ \(0\)\
\-\ has\\:\\ 0\\.004845108606564849\ \(0\)\
\-\ lesions\\:\\ 0\\.004834819910751097\ \(0\)\
\-\ 3\\:\\ 0\\.0048332742190979215\ \(0\)\
\-\ prevalence\\:\\ 0\\.004764647067461127\ \(0\)\
\-\ were\\:\\ 0\\.004686681972680969\ \(0\)\
\-\ risk\\:\\ 0\\.004672715349273983\ \(0\)\
\-\ purple\\:\\ 0\\.004659967473006273\ \(0\)\
\-\ nat\\:\\ 0\\.004659967473006273\ \(0\)\
\-\ resulting\\:\\ 0\\.004532516172632284\ \(0\)\
\-\ granules\\:\\ 0\\.004486246414762444\ \(0\)\
\-\ endothelium\\:\\ 0\\.004486246414762444\ \(0\)\
\-\ streptococcal\\:\\ 0\\.004486246414762444\ \(0\)\
\-\ 1\\-4\\:\\ 0\\.004486246414762444\ \(0\)\
\-\ indicative\\:\\ 0\\.004423634774675881\ \(0\)\
\-\ for\\:\\ 0\\.0044028269845574584\ \(0\)\
\-\ inferior\\:\\ 0\\.004376987260505832\ \(0\)\
\-\ chronic\\:\\ 0\\.004360488465411232\ \(0\)\
\-\ mouth\\:\\ 0\\.0043552402524764736\ \(0\)\
\-\ features\\:\\ 0\\.004355111438556857\ \(0\)\
\-\ electron\\:\\ 0\\.004351497893437438\ \(0\)\
\-\ nephrotic\\:\\ 0\\.004351497893437438\ \(0\)\
\-\ serologic\\:\\ 0\\.004351497893437438\ \(0\)\
\-\ arms\\:\\ 0\\.004322886916786185\ \(0\)\
\-\ asthma\\:\\ 0\\.004276425599406158\ \(0\)\
\-\ is\\:\\ 0\\.0042443446436045106\ \(0\)\
\-\ tapered\\:\\ 0\\.004241400334986982\ \(0\)\
\-\ rheumatologist\\:\\ 0\\.004241400334986982\ \(0\)\
\-\ deaths\\:\\ 0\\.004241400334986982\ \(0\)\
\-\ thrombocytopenic\\:\\ 0\\.004241400334986982\ \(0\)\
\-\ data\\:\\ 0\\.0041900939148007904\ \(0\)\
\-\ was\\:\\ 0\\.00417750160356027\ \(0\)\
\-\ visualized\\:\\ 0\\.0041774542865875425\ \(0\)\
\-\ continue\\:\\ 0\\.0041764726490720406\ \(0\)\
\-\ oophorectomy\\:\\ 0\\.004148314175671005\ \(0\)\
\-\ esrd\\:\\ 0\\.004148314175671005\ \(0\)\
\-\ project\\:\\ 0\\.004148314175671005\ \(0\)\
\-\ complex\\:\\ 0\\.004132718451224803\ \(0\)\
\-\ medial\\:\\ 0\\.004126357961337639\ \(0\)\
\-\ ua\\:\\ 0\\.004111279261730474\ \(0\)\
\-\ non\\-tender\\:\\ 0\\.004098785310523648\ \(0\)\
\-\ what\\:\\ 0\\.004086461350328196\ \(0\)\
\-\ necrosis\\:\\ 0\\.0040737931321795946\ \(0\)\
\-\ effectiveness\\:\\ 0\\.004067679276743153\ \(0\)\
\-\ rev\\:\\ 0\\.004067679276743153\ \(0\)\
\-\ left\\:\\ 0\\.004041507780742997\ \(0\)\
\-\ patients\\:\\ 0\\.004006475723489177\ \(0\)\
\-\ petechiae\\:\\ 0\\.003996554255211521\ \(0\)\
\-\ bx\\:\\ 0\\.003996554255211521\ \(0\)\
\-\ preceding\\:\\ 0\\.003996554255211521\ \(0\)\
\-\ midline\\:\\ 0\\.003992910733500629\ \(0\)\
\-\ website\\:\\ 0\\.003932930755418148\ \(0\)\
\-\ 50\\:\\ 0\\.003926326107057735\ \(0\)\
\-\ no\\:\\ 0\\.0038969390883324367\ \(0\)\
\-\ its\\:\\ 0\\.003894361646685557\ \(0\)\
\-\ proliferative\\:\\ 0\\.0038753762990145694\ \(0\)\
\-\ studies\\:\\ 0\\.003854469707462753\ \(0\)\
\-\ overall\\:\\ 0\\.0038506976743647304\ \(0\)\
\-\ progression\\:\\ 0\\.0038506976743647304\ \(0\)\
\-\ there\\:\\ 0\\.0038397208830464632\ \(0\)\
\-\ bruises\\:\\ 0\\.0038228331969676916\ \(0\)\
\-\ laboratory\\:\\ 0\\.0038032508887126397\ \(0\)\
\-\ rheumatology\\:\\ 0\\.0037744982285657976\ \(0\)\
\-\ evaluation\\:\\ 0\\.00374734117727477\ \(0\)\
\-\ serum\\:\\ 0\\.0037356617225881837\ \(0\)\
\-\ on\\:\\ 0\\.003715624157672789\ \(0\)\
\-\ uri\\:\\ 0\\.0036491121387238626\ \(0\)\
\-\ without\\:\\ 0\\.0036449513883300005\ \(0\)\
\-\ imaging\\:\\ 0\\.0036269453341587006\ \(0\)\
\-\ spots\\:\\ 0\\.0036125030675786727\ \(0\)\
\-\ performed\\:\\ 0\\.003596887577335928\ \(0\)\
\-\ urinary\\:\\ 0\\.003583067046743502\ \(0\)\
\-\ dermatitis\\:\\ 0\\.0035779871171922302\ \(0\)\
\-\ right\\:\\ 0\\.003539013350976877\ \(0\)\
\-\ control\\:\\ 0\\.0035285665744007005\ \(0\)\
\-\ are\\:\\ 0\\.0035171312576376865\ \(0\)\
\-\ sonogram\\:\\ 0\\.003514363617398857\ \(0\)\
\-\ inside\\:\\ 0\\.003514363617398857\ \(0\)\
\-\ erythematosus\\:\\ 0\\.003514363617398857\ \(0\)\
\-\ been\\:\\ 0\\.0035096541205676193\ \(0\)\
\-\ less\\:\\ 0\\.0034950966235781184\ \(0\)\
\-\ few\\:\\ 0\\.0034834285547015375\ \(0\)\
\-\ it\\:\\ 0\\.0034797977980670592\ \(0\)\
\-\ important\\:\\ 0\\.0034771600376321773\ \(0\)\
\-\ possible\\:\\ 0\\.0034758239358503285\ \(0\)\
\-\ recent\\:\\ 0\\.00346946745028961\ \(0\)\
\-\ up\\:\\ 0\\.003468972148330651\ \(0\)\
\-\ sclerotic\\:\\ 0\\.0034647516641193496\ \(0\)\
\-\ cellular\\:\\ 0\\.003456809160995279\ \(0\)\
\-\ centers\\:\\ 0\\.003456809160995279\ \(0\)\
\-\ medications\\:\\ 0\\.0034525109764683326\ \(0\)\
\-\ pink\\:\\ 0\\.0034299663092012974\ \(0\)\
\-\ hysterectomy\\:\\ 0\\.0034299663092012974\ \(0\)\
\-\ x\\:\\ 0\\.003404669487134634\ \(0\)\
\-\ bilaterally\\:\\ 0\\.003389740626236598\ \(0\)\
\-\ per\\:\\ 0\\.0033879933050114776\ \(0\)\
\-\ which\\:\\ 0\\.0033713804682058697\ \(0\)\
\-\ these\\:\\ 0\\.00335725346008128\ \(0\)\
\-\ description\\:\\ 0\\.003355931090546507\ \(0\)\
\-\ platelets\\:\\ 0\\.003355931090546507\ \(0\)\
\-\ a\\:\\ 0\\.00335289687527803\ \(0\)\
\-\ c4\\:\\ 0\\.003333141037416769\ \(0\)\
\-\ aorta\\:\\ 0\\.0033224854593777585\ \(0\)\
\-\ cortex\\:\\ 0\\.0033120136999564937\ \(0\)\
\-\ measures\\:\\ 0\\.0033120136999564937\ \(0\)\
\-\ together\\:\\ 0\\.0033111798996324237\ \(0\)\
\-\ both\\:\\ 0\\.0032943840439102075\ \(0\)\
\-\ al\\:\\ 0\\.003281305772714029\ \(0\)\
\-\ diagnose\\:\\ 0\\.003269517537623395\ \(0\)\
\-\ any\\:\\ 0\\.003249800764580065\ \(0\)\
\-\ consisting\\:\\ 0\\.003249716919976662\ \(0\)\
\-\ hospitalization\\:\\ 0\\.0032119630812198173\ \(0\)\
\-\ surveillance\\:\\ 0\\.0032119630812198173\ \(0\)\
\-\ https\\:\\ 0\\.0032119630812198173\ \(0\)\
\-\ formation\\:\\ 0\\.0031949740881086625\ \(0\)\
\-\ limits\\:\\ 0\\.0031904108688786286\ \(0\)\
\-\ et\\:\\ 0\\.003167933360618009\ \(0\)\
\-\ during\\:\\ 0\\.0031582237317920384\ \(0\)\
\-\ epithelial\\:\\ 0\\.0031428747049047543\ \(0\)\
\-\ morbidity\\:\\ 0\\.0031428747049047543\ \(0\)\
\-\ considering\\:\\ 0\\.0031428747049047543\ \(0\)\
\-\ bladder\\:\\ 0\\.003141676533740063\ \(0\)\
\-\ mature\\:\\ 0\\.003111085010771046\ \(0\)\
\-\ routine\\:\\ 0\\.0031036654838315194\ \(0\)\
\-\ cells\\:\\ 0\\.0031036654838315194\ \(0\)\
\-\ sized\\:\\ 0\\.003095796479379566\ \(0\)\
\-\ negative\\:\\ 0\\.0030822707262981573\ \(0\)\
\-\ 6\\:\\ 0\\.0030822707262981573\ \(0\)\
\-\ attached\\:\\ 0\\.003066333819856962\ \(0\)\
\-\ prednisone\\:\\ 0\\.0030521245822904197\ \(0\)\
\-\ variety\\:\\ 0\\.0030521245822904197\ \(0\)\
\-\ how\\:\\ 0\\.0030521245822904197\ \(0\)\
\-\ years\\:\\ 0\\.003030486880457104\ \(0\)\
\-\ agents\\:\\ 0\\.0030246714578479337\ \(0\)\
\-\ pathological\\:\\ 0\\.0030113991711820066\ \(0\)\
\-\ rare\\:\\ 0\\.003005751991551899\ \(0\)\
\-\ of\\:\\ 0\\.002989982810334848\ \(0\)\
\-\ estimated\\:\\ 0\\.002985698920929111\ \(0\)\
\-\ about\\:\\ 0\\.00298374774103646\ \(0\)\
\-\ not\\:\\ 0\\.0029826537964781044\ \(0\)\
\-\ rubs\\:\\ 0\\.0029610479580545602\ \(0\)\
\-\ classification\\:\\ 0\\.00294908984978392\ \(0\)\
\-\ time\\:\\ 0\\.0029149773275837106\ \(0\)\
\-\ this\\:\\ 0\\.0029019843397165854\ \(0\)\
\-\ throughout\\:\\ 0\\.002897416056431093\ \(0\)\
\-\ specifically\\:\\ 0\\.002892612761613133\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.002890852280597065\ \(0\)\
\-\ 8\\.\\:\\ 0\\.00288192461119079\ \(0\)\
\-\ 4\\:\\ 0\\.0028755699337911175\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.0028746479646996237\ \(0\)\
\-\ illness\\:\\ 0\\.0028714223510990814\ \(0\)\
\-\ diagnosed\\:\\ 0\\.0028461912652128674\ \(0\)\
\-\ involvement\\:\\ 0\\.0028369009570904133\ \(0\)\
\-\ consists\\:\\ 0\\.002831149781957371\ \(0\)\
\-\ case\\:\\ 0\\.002822319494062909\ \(0\)\
\-\ dark\\:\\ 0\\.002821487740081501\ \(0\)\
\-\ mortality\\:\\ 0\\.002811977862685281\ \(0\)\
\-\ percent\\:\\ 0\\.002811977862685281\ \(0\)\
\-\ later\\:\\ 0\\.002794763261768953\ \(0\)\
\-\ incomplete\\:\\ 0\\.0027843150993813602\ \(0\)\
\-\ final\\:\\ 0\\.0027843150993813602\ \(0\)\
\-\ had\\:\\ 0\\.0027835897029600066\ \(0\)\
\-\ 2\\:\\ 0\\.002777935532171718\ \(0\)\
\-\ follows\\:\\ 0\\.002775368791540091\ \(0\)\
\-\ \\-\\:\\ 0\\.002765290547566974\ \(0\)\
\-\ therapy\\:\\ 0\\.002759228014783349\ \(0\)\
\-\ damage\\:\\ 0\\.002757864240288127\ \(0\)\
\-\ due\\:\\ 0\\.0027539579141942507\ \(0\)\
\-\ but\\:\\ 0\\.002751363679096524\ \(0\)\
\-\ 7\\.\\:\\ 0\\.002749298639447574\ \(0\)\
\-\ systems\\:\\ 0\\.002740852841153649\ \(0\)\
\-\ every\\:\\ 0\\.002740852841153649\ \(0\)\
\-\ 2001\\:\\ 0\\.002740852841153649\ \(0\)\
\-\ vena\\:\\ 0\\.0027325235403490985\ \(0\)\
\-\ rom\\:\\ 0\\.0027243075668854635\ \(0\)\
\-\ cava\\:\\ 0\\.002716201878279099\ \(0\)\
\-\ new\\:\\ 0\\.002697271718116448\ \(0\)\
\-\ african\\:\\ 0\\.002692517872751755\ \(0\)\
\-\ red\\:\\ 0\\.002692517872751755\ \(0\)\
\-\ 241\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ non\\-inflamed\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 03\\/23\\/13\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 03\\/19\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 03\\/23\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ immunology\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 03\\/20\\/13\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ ds\\-dna\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ histone\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 3\\/21\\/13\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ ratio\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ urine\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ protein\\/creatinine\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 552\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 09\\/12\\/2017\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ glomeruli\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ tubulointerstitium\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ vessels\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ periglomerular\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ arterioles\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ c1q\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ mesangial\\/paramesangial\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ subepithelial\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ endocapillary\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ tubuloredicular\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ simplification\\/effacement\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ fenestrations\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ kidney\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ comment\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ icd\\-10\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ r31\\.9\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ jets\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ titles\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ nephropthy\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 3\\/19\\/2013\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ \\/10\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 555\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 650\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ maternal\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ paternal\\-\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ billion\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ dollars\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ medicaid\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ ect\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ co\\-morbidity\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ mesangium\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 3\\.class\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ electron\\-dense\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ acei\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ arb\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ reassuringly\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ xu\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ kochanek\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ bastian\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ www\\.cdc\\.gov\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ race\\/ethnicity\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ portielje\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ westendorp\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ rg\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ kluin\\-nelemans\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ brand\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 97\\:2549\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ fakhouri\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ fr\\√\\©meaux\\-bacchi\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ no\\√\\´l\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ glomerulopathy\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 6\\:494\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ bomback\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ glomerulopathies\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 8\\:634\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ kuypers\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ evenepoel\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ \\'full\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ membranoproliferative\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ dial\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 16\\:2258\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ rabasco\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ cavero\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ rom\\√\\°n\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ 88\\:1153\\:\\ 0\\.002661690345400513\ \(0\)\
\-\ mechanism\\:\\ 0\\.002654998681262017\ \(0\)\
\-\ dominant\\:\\ 0\\.0026335574442711293\ \(0\)\
\-\ medication\\:\\ 0\\.002599431713435778\ \(0\)\
\-\ unremarkable\\:\\ 0\\.0025625601618496927\ \(0\)\
\-\ also\\:\\ 0\\.0025432059083184654\ \(0\)\
\-\ showed\\:\\ 0\\.002537865278916392\ \(0\)\
\-\ increased\\:\\ 0\\.0025247400746372653\ \(0\)\
\-\ interstitial\\:\\ 0\\.0025246313017734676\ \(0\)\
\-\ aggressive\\:\\ 0\\.0025246313017734676\ \(0\)\
\-\ appreciated\\:\\ 0\\.002513018160512666\ \(0\)\
\-\ 6\\.\\:\\ 0\\.0025072942813130624\ \(0\)\
\-\ unusual\\:\\ 0\\.0024960067613781873\ \(0\)\
\-\ testing\\:\\ 0\\.0024960067613781873\ \(0\)\
\-\ superior\\:\\ 0\\.002471688131389666\ \(0\)\
\-\ systemic\\:\\ 0\\.002468677901723525\ \(0\)\
\-\ 2\\.\\:\\ 0\\.0024614530269929874\ \(0\)\
\-\ follow\\:\\ 0\\.002459419811545683\ \(0\)\
\-\ past\\:\\ 0\\.002459419811545683\ \(0\)\
\-\ american\\:\\ 0\\.00245808351183771\ \(0\)\
\-\ become\\:\\ 0\\.00245808351183771\ \(0\)\
\-\ 1\\:\\ 0\\.0024557081738643804\ \(0\)\
\-\ c\\:\\ 0\\.0024528552130797907\ \(0\)\
\-\ 130\\/80\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ 44\\.1\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ glasses\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ pos\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ ssa\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ cores\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ ailments\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ anti\\-dna\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ figure1\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ photosensitivity\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ seafood\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ spending\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ auto\\-antibodies\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ hosts\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ preventative\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ algorithm\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ immunosuppressives\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ therapeutically\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ informative\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ appel\\:\\ 0\\.0024524067763908673\ \(0\)\
\-\ prognosis\\:\\ 0\\.0024476717929762934\ \(0\)\
\-\ found\\:\\ 0\\.002439334795699377\ \(0\)\
\-\ dense\\:\\ 0\\.0024374365524486527\ \(0\)\
\-\ associated\\:\\ 0\\.002435341258342635\ \(0\)\
\-\ phase\\:\\ 0\\.002427371907228114\ \(0\)\
\-\ the\\:\\ 0\\.0024210321596649445\ \(0\)\
\-\ current\\:\\ 0\\.002417472263643768\ \(0\)\
\-\ teratoma\\:\\ 0\\.0024125826439380803\ \(0\)\
\-\ light\\:\\ 0\\.002407732298710264\ \(0\)\
\-\ tubular\\:\\ 0\\.00240292060206221\ \(0\)\
\-\ medical\\:\\ 0\\.0023816211957119605\ \(0\)\
\-\ clinical\\:\\ 0\\.0023816211957119605\ \(0\)\
\-\ having\\:\\ 0\\.002370271313855522\ \(0\)\
\-\ incidence\\:\\ 0\\.002365747961362069\ \(0\)\
\-\ joints\\:\\ 0\\.0023612582400531815\ \(0\)\
\-\ idiopathic\\:\\ 0\\.0023523777162671334\ \(0\)\
\-\ 16\\:\\ 0\\.0023349991144857064\ \(0\)\
\-\ 13\\:\\ 0\\.0023307315014282834\ \(0\)\
\-\ landmarks\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ non\\-enlarged\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ immunofluorescence\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ ensue\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ statistics\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ singular\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ dipstick\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ immunotherapy\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ jq\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ ba\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ smet\\:\\ 0\\.0023299837365031366\ \(0\)\
\-\ only\\:\\ 0\\.00232736563268563\ \(0\)\
\-\ numerous\\:\\ 0\\.0023139564023298077\ \(0\)\
\-\ cbc\\:\\ 0\\.002305740428866173\ \(0\)\
\-\ started\\:\\ 0\\.0023016739843122217\ \(0\)\
\-\ needed\\:\\ 0\\.002247444579202739\ \(0\)\
\-\ loss\\:\\ 0\\.002246797257670688\ \(0\)\
\-\ ro\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ ua\\-\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ pmn\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ kappa\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ 13\\.5\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ normocytic\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ hematology\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ focusing\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ plausible\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ straightforward\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ surprisingly\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ portosystemic\\:\\ 0\\.002243123207381222\ \(0\)\
\-\ bleeding\\:\\ 0\\.0022400802838562304\ \(0\)\
\-\ affected\\:\\ 0\\.00223280471711941\ \(0\)\
\-\ 5\\.\\:\\ 0\\.0022256157663305704\ \(0\)\
\-\ screening\\:\\ 0\\.002201107746937407\ \(0\)\
\-\ suggest\\:\\ 0\\.0021976864078458148\ \(0\)\
\-\ inflammation\\:\\ 0\\.002194284344006288\ \(0\)\
\-\ addition\\:\\ 0\\.0021875371818093525\ \(0\)\
\-\ ed\\:\\ 0\\.002180864575416487\ \(0\)\
\-\ denies\\:\\ 0\\.0021775557192784283\ \(0\)\
\-\ pearly\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ mild\\-moderate\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ 10\\-25\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ 3\\/10\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ code\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ 12\\.7\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ 35\\-year\\-old\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ 2017\\.\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ public\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ 152\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ lm\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ lowering\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ cohort\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ amongst\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ 2013\\.\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ hc\\:\\ 0\\.002175748946718719\ \(0\)\
\-\ general\\:\\ 0\\.0021742648951434255\ \(0\)\
\-\ include\\:\\ 0\\.002171334681186854\ \(0\)\
\-\ previously\\:\\ 0\\.002167736564162619\ \(0\)\
\-\ neurologic\\:\\ 0\\.0021548878936026644\ \(0\)\
\-\ taken\\:\\ 0\\.0021517179927052345\ \(0\)\
\-\ nodules\\:\\ 0\\.0021392022134074586\ \(0\)\
\-\ history\\:\\ 0\\.0021380698146867454\ \(0\)\
\-\ same\\:\\ 0\\.002126940579252419\ \(0\)\
\-\ span\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ 4\\/4\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ lambda\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ fibrinogen\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ 2\\-6\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ non\\-radiating\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ tetanus\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ understand\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ coat\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ ivp\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ surprising\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ 5\\,6\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ kd\\:\\ 0\\.002120700167493491\ \(0\)\
\-\ high\\:\\ 0\\.0021182482437289997\ \(0\)\
\-\ months\\:\\ 0\\.002114077259683032\ \(0\)\
\-\ blood\\:\\ 0\\.0021126911888671193\ \(0\)\
\-\ upon\\:\\ 0\\.0021090026840749334\ \(0\)\
\-\ where\\:\\ 0\\.002106064163754177\ \(0\)\
\-\ if\\:\\ 0\\.0021003110813230396\ \(0\)\
\-\ initially\\:\\ 0\\.002100229676488635\ \(0\)\
\-\ reports\\:\\ 0\\.0020802417849268328\ \(0\)\
\-\ pigmentation\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ non\\-erythematous\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ pas\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ microscopy\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ im\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ sl\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ lh\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ immunohistochemical\\:\\ 0\\.0020741570878355024\ \(0\)\
\-\ typical\\:\\ 0\\.002069110322554346\ \(0\)\
\-\ shown\\:\\ 0\\.002069110322554346\ \(0\)\
\-\ sounds\\:\\ 0\\.0020581803457164127\ \(0\)\
\-\ prick\\:\\ 0\\.0020338396383715765\ \(0\)\
\-\ zero\\:\\ 0\\.0020338396383715765\ \(0\)\
\-\ imperative\\:\\ 0\\.0020338396383715765\ \(0\)\
\-\ 7\\.0\\:\\ 0\\.0020338396383715765\ \(0\)\
\-\ inactive\\:\\ 0\\.0020338396383715765\ \(0\)\
\-\ induction\\:\\ 0\\.0020338396383715765\ \(0\)\
\-\ 2016\\.\\:\\ 0\\.0020338396383715765\ \(0\)\
\-\ 4\\.\\:\\ 0\\.0020316908033821243\ \(0\)\
\-\ rate\\:\\ 0\\.002011305247871886\ \(0\)\
\-\ previous\\:\\ 0\\.002003834661034599\ \(0\)\
\-\ pmi\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ sm\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ relapse\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ captions\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ g1p1\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ elbows\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ plays\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ manifested\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ debate\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ je\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ house\\:\\ 0\\.0019982771276057603\ \(0\)\
\-\ process\\:\\ 0\\.001986754519827726\ \(0\)\
\-\ texture\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ prescription\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ wheeze\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ capillaries\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ insomnia\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ works\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ ever\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ nih\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ efforts\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ host\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ traditionally\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ earliest\\:\\ 0\\.001966465377709074\ \(0\)\
\-\ course\\:\\ 0\\.0019471808233427785\ \(0\)\
\-\ referred\\:\\ 0\\.0019471808233427785\ \(0\)\
\-\ lag\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ conjunctiva\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ perirenal\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ jet\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ daughter\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ silent\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ reach\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ published\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ gb\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ int\\:\\ 0\\.0019376881495072847\ \(0\)\
\-\ abdominal\\:\\ 0\\.0019347094548207565\ \(0\)\
\-\ 8\\:\\ 0\\.001929418815367964\ \(0\)\
\-\ weakness\\:\\ 0\\.0019164319764664157\ \(0\)\
\-\ anicteric\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ dentition\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ auscultated\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ random\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ endothelial\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ lft\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ context\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ carry\\:\\ 0\\.0019114165984838458\ \(0\)\
\-\ breast\\:\\ 0\\.0019037185651150676\ \(0\)\
\-\ consistent\\:\\ 0\\.0018979150985789883\ \(0\)\
\-\ min\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ nares\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ carotids\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ 5\\.0\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ begun\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ urgency\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ 1\\-3\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ awareness\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ nephropathy\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ records\\:\\ 0\\.0018872491142828988\ \(0\)\
\-\ middle\\:\\ 0\\.0018871732908468826\ \(0\)\
\-\ early\\:\\ 0\\.0018871732908468826\ \(0\)\
\-\ presence\\:\\ 0\\.001873058948343677\ \(0\)\
\-\ lid\\:\\ 0\\.0018648735188258572\ \(0\)\
\-\ interlobular\\:\\ 0\\.0018648735188258572\ \(0\)\
\-\ antibodies\\:\\ 0\\.0018648735188258572\ \(0\)\
\-\ said\\:\\ 0\\.0018648735188258572\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.0018648735188258572\ \(0\)\
\-\ they\\:\\ 0\\.0018592669845937837\ \(0\)\
\-\ muscle\\:\\ 0\\.0018534512279144593\ \(0\)\
\-\ babinski\\:\\ 0\\.001844042337821343\ \(0\)\
\-\ eosinophils\\:\\ 0\\.001844042337821343\ \(0\)\
\-\ real\\-time\\:\\ 0\\.001844042337821343\ \(0\)\
\-\ substantial\\:\\ 0\\.001844042337821343\ \(0\)\
\-\ accurately\\:\\ 0\\.001844042337821343\ \(0\)\
\-\ february\\:\\ 0\\.001844042337821343\ \(0\)\
\-\ noted\\:\\ 0\\.001834620641714306\ \(0\)\
\-\ 5\\.1\\:\\ 0\\.0018245560693619313\ \(0\)\
\-\ 16\\.\\:\\ 0\\.0018245560693619313\ \(0\)\
\-\ helped\\:\\ 0\\.0018245560693619313\ \(0\)\
\-\ eventual\\:\\ 0\\.0018062515337893363\ \(0\)\
\-\ stabilized\\:\\ 0\\.0018062515337893363\ \(0\)\
\-\ why\\:\\ 0\\.0018062515337893363\ \(0\)\
\-\ consisted\\:\\ 0\\.0018062515337893363\ \(0\)\
\-\ retrospective\\:\\ 0\\.0018062515337893363\ \(0\)\
\-\ labs\\:\\ 0\\.0017946702940429577\ \(0\)\
\-\ weighing\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ pin\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ 20\\-30\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ adequately\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ 14\\.\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ transfusions\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ crampy\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ irregularities\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ greatly\\:\\ 0\\.0017889935585961151\ \(0\)\
\-\ other\\:\\ 0\\.0017840928883174354\ \(0\)\
\-\ sclera\\:\\ 0\\.001772668914492771\ \(0\)\
\-\ grey\\:\\ 0\\.001772668914492771\ \(0\)\
\-\ 5\\-10\\:\\ 0\\.001772668914492771\ \(0\)\
\-\ igg\\:\\ 0\\.001772668914492771\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.001772668914492771\ \(0\)\
\-\ 3\\.\\:\\ 0\\.0017656245242395694\ \(0\)\
\-\ ana\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ zones\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ 5\\.5\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ 13\\.\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ buttocks\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ bruising\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ lives\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ allowed\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ limit\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ categories\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ lipid\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ ad\\:\\ 0\\.0017571818086994284\ \(0\)\
\-\ at\\:\\ 0\\.0017478308466661126\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0017443190809155115\ \(0\)\
\-\ although\\:\\ 0\\.0017427109182225867\ \(0\)\
\-\ quadrants\\:\\ 0\\.0017424504789381263\ \(0\)\
\-\ ab\\:\\ 0\\.0017424504789381263\ \(0\)\
\-\ plasma\\:\\ 0\\.0017424504789381263\ \(0\)\
\-\ investigation\\:\\ 0\\.0017424504789381263\ \(0\)\
\-\ bmi\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ tm\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ calculi\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ 12\\.\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ exclusion\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ therapies\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ gender\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ 2015\\:\\ 0\\.0017284045804976395\ \(0\)\
\-\ by\\:\\ 0\\.0017184431198609598\ \(0\)\
\-\ global\\:\\ 0\\.0017149831546006487\ \(0\)\
\-\ 15\\.\\:\\ 0\\.0017149831546006487\ \(0\)\
\-\ ha\\:\\ 0\\.0017149831546006487\ \(0\)\
\-\ interestingly\\:\\ 0\\.0017149831546006487\ \(0\)\
\-\ initial\\:\\ 0\\.001709892598598616\ \(0\)\
\-\ out\\:\\ 0\\.0017053465439966884\ \(0\)\
\-\ \\.\\:\\ 0\\.0017042349756878194\ \(0\)\
\-\ inspection\\:\\ 0\\.0017021330294742004\ \(0\)\
\-\ illicit\\:\\ 0\\.0017021330294742004\ \(0\)\
\-\ study\\:\\ 0\\.0016978450222584294\ \(0\)\
\-\ phases\\:\\ 0\\.0016898075480369255\ \(0\)\
\-\ varies\\:\\ 0\\.0016898075480369255\ \(0\)\
\-\ ii\\-xii\\:\\ 0\\.0016779655452732534\ \(0\)\
\-\ responsible\\:\\ 0\\.0016779655452732534\ \(0\)\
\-\ decision\\:\\ 0\\.0016779655452732534\ \(0\)\
\-\ have\\:\\ 0\\.0016761214477944671\ \(0\)\
\-\ bpm\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ respirations\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ perrla\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ ears\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ cmp\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ albumin\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ consist\\:\\ 0\\.0016665705187083844\ \(0\)\
\-\ atraumatic\\:\\ 0\\.0016555899498162119\ \(0\)\
\-\ fibroids\\:\\ 0\\.0016555899498162119\ \(0\)\
\-\ decades\\:\\ 0\\.0016555899498162119\ \(0\)\
\-\ often\\:\\ 0\\.0016464212249514807\ \(0\)\
\-\ injury\\:\\ 0\\.0016450534673241545\ \(0\)\
\-\ plt\\:\\ 0\\.0016449947445591859\ \(0\)\
\-\ microscopic\\:\\ 0\\.0016449947445591859\ \(0\)\
\-\ 2012\\:\\ 0\\.0016449947445591859\ \(0\)\
\-\ moist\\:\\ 0\\.0016347587688116975\ \(0\)\
\-\ indication\\:\\ 0\\.0016347587688116975\ \(0\)\
\-\ dm\\:\\ 0\\.0016347587688116975\ \(0\)\
\-\ office\\:\\ 0\\.0016347587688116975\ \(0\)\
\-\ histologic\\:\\ 0\\.0016347587688116975\ \(0\)\
\-\ post\\:\\ 0\\.0016249003822900324\ \(0\)\
\-\ accounts\\:\\ 0\\.001624858459988331\ \(0\)\
\-\ regimen\\:\\ 0\\.001615272500352286\ \(0\)\
\-\ heat\\:\\ 0\\.001615272500352286\ \(0\)\
\-\ aids\\:\\ 0\\.001615272500352286\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0016118292067014497\ \(0\)\
\-\ 11\\.\\:\\ 0\\.0016059815406099087\ \(0\)\
\-\ intolerance\\:\\ 0\\.0016059815406099087\ \(0\)\
\-\ likelihood\\:\\ 0\\.0016059815406099087\ \(0\)\
\-\ begins\\:\\ 0\\.0016059815406099087\ \(0\)\
\-\ murphy\\:\\ 0\\.0016059815406099087\ \(0\)\
\-\ 10\\.\\:\\ 0\\.001596967964779691\ \(0\)\
\-\ 2010\\:\\ 0\\.001596967964779691\ \(0\)\
\-\ female\\:\\ 0\\.0015912683618186899\ \(0\)\
\-\ eomi\\:\\ 0\\.001588215689153709\ \(0\)\
\-\ august\\:\\ 0\\.001588215689153709\ \(0\)\
\-\ photophobia\\:\\ 0\\.001588215689153709\ \(0\)\
\-\ constipation\\:\\ 0\\.001588215689153709\ \(0\)\
\-\ normocephalic\\:\\ 0\\.00157970998958647\ \(0\)\
\-\ them\\:\\ 0\\.00157970998958647\ \(0\)\
\-\ mmhg\\:\\ 0\\.0015714373524523771\ \(0\)\
\-\ hemoglobin\\:\\ 0\\.0015714373524523771\ \(0\)\
\-\ severely\\:\\ 0\\.0015714373524523771\ \(0\)\
\-\ 78\\:\\ 0\\.0015633853454831256\ \(0\)\
\-\ finally\\:\\ 0\\.0015633853454831256\ \(0\)\
\-\ rhonchi\\:\\ 0\\.001555542505385523\ \(0\)\
\-\ proliferation\\:\\ 0\\.001555542505385523\ \(0\)\
\-\ month\\:\\ 0\\.001548076413526938\ \(0\)\
\-\ documented\\:\\ 0\\.001547898239689783\ \(0\)\
\-\ gallops\\:\\ 0\\.0015404427407192604\ \(0\)\
\-\ identify\\:\\ 0\\.0015404427407192604\ \(0\)\
\-\ smoker\\:\\ 0\\.001533166909928481\ \(0\)\
\-\ already\\:\\ 0\\.001533166909928481\ \(0\)\
\-\ e\\:\\ 0\\.001533166909928481\ \(0\)\
\-\ primary\\:\\ 0\\.0015286136853234881\ \(0\)\
\-\ prominence\\:\\ 0\\.0015260622911452098\ \(0\)\
\-\ heard\\:\\ 0\\.0015260622911452098\ \(0\)\
\-\ role\\:\\ 0\\.0015260622911452098\ \(0\)\
\-\ interesting\\:\\ 0\\.0015260622911452098\ \(0\)\
\-\ g\\:\\ 0\\.0015260622911452098\ \(0\)\
\-\ ulcers\\:\\ 0\\.0015191210114879942\ \(0\)\
\-\ prescribed\\:\\ 0\\.0015191210114879942\ \(0\)\
\-\ never\\:\\ 0\\.0015191210114879942\ \(0\)\
\-\ membranes\\:\\ 0\\.0015123357289239668\ \(0\)\
\-\ organ\\:\\ 0\\.0015123357289239668\ \(0\)\
\-\ ureteral\\:\\ 0\\.0015123357289239668\ \(0\)\
\-\ 9\\.\\:\\ 0\\.0015123357289239668\ \(0\)\
\-\ appetite\\:\\ 0\\.0015123357289239668\ \(0\)\
\-\ allergies\\:\\ 0\\.0015123357289239668\ \(0\)\
\-\ effects\\:\\ 0\\.0015056995855910033\ \(0\)\
\-\ sob\\:\\ 0\\.0015056995855910033\ \(0\)\
\-\ social\\:\\ 0\\.0015056995855910033\ \(0\)\
\-\ individuals\\:\\ 0\\.0015056995855910033\ \(0\)\
\-\ 3\\.5\\:\\ 0\\.0015056995855910033\ \(0\)\
\-\ scarring\\:\\ 0\\.0015056995855910033\ \(0\)\
\-\ knees\\:\\ 0\\.0014992061661402293\ \(0\)\
\-\ cystic\\:\\ 0\\.0014883047749104821\ \(0\)\
\-\ lbs\\:\\ 0\\.0014866238302704924\ \(0\)\
\-\ nose\\:\\ 0\\.0014866238302704924\ \(0\)\
\-\ affect\\:\\ 0\\.0014866238302704924\ \(0\)\
\-\ with\\:\\ 0\\.0014837486098355584\ \(0\)\
\-\ visit\\:\\ 0\\.0014805239790272801\ \(0\)\
\-\ question\\:\\ 0\\.0014805239790272801\ \(0\)\
\-\ changes\\:\\ 0\\.0014788937054559543\ \(0\)\
\-\ within\\:\\ 0\\.0014765683046975378\ \(0\)\
\-\ syndrome\\:\\ 0\\.0014757889956127062\ \(0\)\
\-\ throat\\:\\ 0\\.00147454492489196\ \(0\)\
\-\ creatinine\\:\\ 0\\.001468681976263608\ \(0\)\
\-\ monitor\\:\\ 0\\.001468681976263608\ \(0\)\
\-\ sweats\\:\\ 0\\.001468681976263608\ \(0\)\
\-\ effective\\:\\ 0\\.001468681976263608\ \(0\)\
\-\ following\\:\\ 0\\.0014645397082736402\ \(0\)\
\-\ edema\\:\\ 0\\.0014594948607676876\ \(0\)\
\-\ all\\:\\ 0\\.0014594948607676876\ \(0\)\
\-\ deformities\\:\\ 0\\.001457286949698739\ \(0\)\
\-\ treat\\:\\ 0\\.001457286949698739\ \(0\)\
\-\ produced\\:\\ 0\\.001457286949698739\ \(0\)\
\-\ therapeutic\\:\\ 0\\.0014517467508254913\ \(0\)\
\-\ tone\\:\\ 0\\.0014463063808065665\ \(0\)\
\-\ against\\:\\ 0\\.0014463063808065665\ \(0\)\
\-\ a\\.\\:\\ 0\\.0014463063808065665\ \(0\)\
\-\ secondary\\:\\ 0\\.0014426509459594247\ \(0\)\
\-\ stability\\:\\ 0\\.001440962305595395\ \(0\)\
\-\ 5\\/5\\:\\ 0\\.0014357111755495407\ \(0\)\
\-\ smith\\:\\ 0\\.0014357111755495407\ \(0\)\
\-\ ratio\\:\\ 0\\.0014305498128202832\ \(0\)\
\-\ core\\:\\ 0\\.0014305498128202832\ \(0\)\
\-\ health\\:\\ 0\\.0014305498128202832\ \(0\)\
\-\ future\\:\\ 0\\.0014305498128202832\ \(0\)\
\-\ making\\:\\ 0\\.0014305498128202832\ \(0\)\
\-\ drugs\\:\\ 0\\.0014254751998020523\ \(0\)\
\-\ combined\\:\\ 0\\.0014254751998020523\ \(0\)\
\-\ transplant\\:\\ 0\\.0014254751998020523\ \(0\)\
\-\ rales\\:\\ 0\\.0014204844685365902\ \(0\)\
\-\ s2\\:\\ 0\\.0014204844685365902\ \(0\)\
\-\ htn\\:\\ 0\\.0014204844685365902\ \(0\)\
\-\ shows\\:\\ 0\\.0014187039249570522\ \(0\)\
\-\ v\\:\\ 0\\.0014155748909786855\ \(0\)\
\-\ 62\\:\\ 0\\.0014107438700407505\ \(0\)\
\-\ discussed\\:\\ 0\\.0014107438700407505\ \(0\)\
\-\ presented\\:\\ 0\\.0014066169293613581\ \(0\)\
\-\ fields\\:\\ 0\\.0014059889313426405\ \(0\)\
\-\ reflex\\:\\ 0\\.0014059889313426405\ \(0\)\
\-\ stated\\:\\ 0\\.0014059889313426405\ \(0\)\
\-\ aneurysmal\\:\\ 0\\.0014013077156011051\ \(0\)\
\-\ capsule\\:\\ 0\\.0013966979716002633\ \(0\)\
\-\ legs\\:\\ 0\\.0013966979716002633\ \(0\)\
\-\ procedures\\:\\ 0\\.0013966979716002633\ \(0\)\
\-\ touch\\:\\ 0\\.0013921575496906801\ \(0\)\
\-\ 2\\-3\\:\\ 0\\.0013921575496906801\ \(0\)\
\-\ eyes\\:\\ 0\\.0013876843957700456\ \(0\)\
\-\ murmurs\\:\\ 0\\.0013876843957700456\ \(0\)\
\-\ cn\\:\\ 0\\.0013876843957700456\ \(0\)\
\-\ collections\\:\\ 0\\.0013876843957700456\ \(0\)\
\-\ managed\\:\\ 0\\.0013876843957700456\ \(0\)\
\-\ spleen\\:\\ 0\\.0013876843957700456\ \(0\)\
\-\ significant\\:\\ 0\\.0013875888593322604\ \(0\)\
\-\ cm\\:\\ 0\\.0013840314721117063\ \(0\)\
\-\ dizziness\\:\\ 0\\.0013832765457032724\ \(0\)\
\-\ wide\\:\\ 0\\.0013832765457032724\ \(0\)\
\-\ support\\:\\ 0\\.0013832765457032724\ \(0\)\
\-\ impression\\:\\ 0\\.0013789321201440636\ \(0\)\
\-\ fatigue\\:\\ 0\\.0013789321201440636\ \(0\)\
\-\ trachea\\:\\ 0\\.0013704264205768246\ \(0\)\
\-\ prostate\\:\\ 0\\.0013704264205768246\ \(0\)\
\-\ percutaneous\\:\\ 0\\.0013662617701745493\ \(0\)\
\-\ mucosa\\:\\ 0\\.0013621537834427318\ \(0\)\
\-\ frequency\\:\\ 0\\.0013621537834427318\ \(0\)\
\-\ we\\:\\ 0\\.0013581009391395494\ \(0\)\
\-\ fact\\:\\ 0\\.0013581009391395494\ \(0\)\
\-\ reduced\\:\\ 0\\.0013581009391395494\ \(0\)\
\-\ evidence\\:\\ 0\\.0013529242653181628\ \(0\)\
\-\ than\\:\\ 0\\.0013520826418588609\ \(0\)\
\-\ equal\\:\\ 0\\.0013501548919422747\ \(0\)\
\-\ musculoskeletal\\:\\ 0\\.0013501548919422747\ \(0\)\
\-\ continues\\:\\ 0\\.0013462589363758776\ \(0\)\
\-\ population\\:\\ 0\\.0013462589363758776\ \(0\)\
\-\ f\\:\\ 0\\.0013462589363758776\ \(0\)\
\-\ late\\:\\ 0\\.0013424126121677163\ \(0\)\
\-\ rhythm\\:\\ 0\\.0013386146706801376\ \(0\)\
\-\ experienced\\:\\ 0\\.0013386146706801376\ \(0\)\
\-\ diarrhea\\:\\ 0\\.0013386146706801376\ \(0\)\
\-\ pulses\\:\\ 0\\.0013348639098110082\ \(0\)\
\-\ each\\:\\ 0\\.0013348639098110082\ \(0\)\
\-\ shunt\\:\\ 0\\.0013348639098110082\ \(0\)\
\-\ mucosal\\:\\ 0\\.001331159171709615\ \(0\)\
\-\ s1\\:\\ 0\\.001331159171709615\ \(0\)\
\-\ atrophy\\:\\ 0\\.001331159171709615\ \(0\)\
\-\ nuclear\\:\\ 0\\.001331159171709615\ \(0\)\
\-\ sinuses\\:\\ 0\\.0013274993406310084\ \(0\)\
\-\ workup\\:\\ 0\\.0013274993406310084\ \(0\)\
\-\ prior\\:\\ 0\\.0013249473262091566\ \(0\)\
\-\ wnl\\:\\ 0\\.0013238833409188358\ \(0\)\
\-\ uterine\\:\\ 0\\.0013238833409188358\ \(0\)\
\-\ p\\:\\ 0\\.0013238833409188358\ \(0\)\
\-\ advanced\\:\\ 0\\.0013203101351075427\ \(0\)\
\-\ possibly\\:\\ 0\\.0013203101351075427\ \(0\)\
\-\ rr\\:\\ 0\\.0013167787221355647\ \(0\)\
\-\ adults\\:\\ 0\\.0013167787221355647\ \(0\)\
\-\ needle\\:\\ 0\\.0013132881356618098\ \(0\)\
\-\ analysis\\:\\ 0\\.0013132881356618098\ \(0\)\
\-\ \\'\\:\\ 0\\.0013098374424783488\ \(0\)\
\-\ 42\\:\\ 0\\.0013064257410127895\ \(0\)\
\-\ possibility\\:\\ 0\\.0013030521599143217\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.001299715856717889\ \(0\)\
\-\ alcohol\\:\\ 0\\.001299715856717889\ \(0\)\
\-\ combination\\:\\ 0\\.001299715856717889\ \(0\)\
\-\ diseases\\:\\ 0\\.001299715856717889\ \(0\)\
\-\ chills\\:\\ 0\\.0012899225971305841\ \(0\)\
\-\ help\\:\\ 0\\.0012867275158109774\ \(0\)\
\-\ develop\\:\\ 0\\.0012867275158109774\ \(0\)\
\-\ d\\:\\ 0\\.0012867275158109774\ \(0\)\
\-\ symptoms\\:\\ 0\\.0012860250464360743\ \(0\)\
\-\ pmh\\:\\ 0\\.00128356589145491\ \(0\)\
\-\ anemia\\:\\ 0\\.00128356589145491\ \(0\)\
\-\ concern\\:\\ 0\\.00128356589145491\ \(0\)\
\-\ prevent\\:\\ 0\\.0012804370306349986\ \(0\)\
\-\ earlier\\:\\ 0\\.0012742749317125328\ \(0\)\
\-\ acute\\:\\ 0\\.0012740817204749367\ \(0\)\
\-\ patent\\:\\ 0\\.0012712404100176347\ \(0\)\
\-\ six\\:\\ 0\\.0012682360830692145\ \(0\)\
\-\ 48\\:\\ 0\\.0012623156508867338\ \(0\)\
\-\ lab\\:\\ 0\\.0012623156508867338\ \(0\)\
\-\ pain\\:\\ 0\\.0012603963375975057\ \(0\)\
\-\ color\\:\\ 0\\.001259398407253963\ \(0\)\
\-\ hr\\:\\ 0\\.001256509080256333\ \(0\)\
\-\ night\\:\\ 0\\.0012536471406565312\ \(0\)\
\-\ surgery\\:\\ 0\\.0012530187586716635\ \(0\)\
\-\ times\\:\\ 0\\.0012508120741257824\ \(0\)\
\-\ completely\\:\\ 0\\.0012397307435550013\ \(0\)\
\-\ disorders\\:\\ 0\\.0012343389508617626\ \(0\)\
\-\ gross\\:\\ 0\\.001229041755918855\ \(0\)\
\-\ still\\:\\ 0\\.001229041755918855\ \(0\)\
\-\ painful\\:\\ 0\\.0012264276065398953\ \(0\)\
\-\ home\\:\\ 0\\.0012264276065398953\ \(0\)\
\-\ reflexes\\:\\ 0\\.001221266243810638\ \(0\)\
\-\ visible\\:\\ 0\\.001221266243810638\ \(0\)\
\-\ states\\:\\ 0\\.001213685953614057\ \(0\)\
\-\ discussion\\:\\ 0\\.001208736131821884\ \(0\)\
\-\ major\\:\\ 0\\.0012062913219690401\ \(0\)\
\-\ form\\:\\ 0\\.0012062913219690401\ \(0\)\
\-\ gait\\:\\ 0\\.001201460301031105\ \(0\)\
\-\ much\\:\\ 0\\.0011943556822478338\ \(0\)\
\-\ t\\:\\ 0\\.0011943556822478338\ \(0\)\
\-\ kidneys\\:\\ 0\\.001187414402590618\ \(0\)\
\-\ 35\\:\\ 0\\.001187414402590618\ \(0\)\
\-\ sensation\\:\\ 0\\.001185135656927761\ \(0\)\
\-\ node\\:\\ 0\\.0011806291200265908\ \(0\)\
\-\ deficits\\:\\ 0\\.0011806291200265908\ \(0\)\
\-\ those\\:\\ 0\\.0011739929766936272\ \(0\)\
\-\ visual\\:\\ 0\\.0011696485511344184\ \(0\)\
\-\ well\\:\\ 0\\.0011673194160438712\ \(0\)\
\-\ lower\\:\\ 0\\.0011605447278767286\ \(0\)\
\-\ focus\\:\\ 0\\.0011590533458773924\ \(0\)\
\-\ factors\\:\\ 0\\.0011590533458773924\ \(0\)\
\-\ report\\:\\ 0\\.0011549172213731165\ \(0\)\
\-\ fibrosis\\:\\ 0\\.001148817370129904\ \(0\)\
\-\ even\\:\\ 0\\.001148817370129904\ \(0\)\
\-\ circumscribed\\:\\ 0\\.0011468111676182287\ \(0\)\
\-\ strength\\:\\ 0\\.001144818207463835\ \(0\)\
\-\ supportive\\:\\ 0\\.0011408713229326295\ \(0\)\
\-\ 14\\:\\ 0\\.0011369753673662322\ \(0\)\
\-\ until\\:\\ 0\\.001133129043158071\ \(0\)\
\-\ their\\:\\ 0\\.0011293311016704925\ \(0\)\
\-\ recurrence\\:\\ 0\\.001125580340801363\ \(0\)\
\-\ 60\\:\\ 0\\.001125580340801363\ \(0\)\
\-\ either\\:\\ 0\\.0011237222896013695\ \(0\)\
\-\ bp\\:\\ 0\\.0011200401419281152\ \(0\)\
\-\ four\\:\\ 0\\.0011200401419281152\ \(0\)\
\-\ using\\:\\ 0\\.0011200401419281152\ \(0\)\
\-\ do\\:\\ 0\\.0011200401419281152\ \(0\)\
\-\ review\\:\\ 0\\.0011182157716213633\ \(0\)\
\-\ total\\:\\ 0\\.0011110265660978973\ \(0\)\
\-\ another\\:\\ 0\\.0011092556966980187\ \(0\)\
\-\ foci\\:\\ 0\\.0011074951531259193\ \(0\)\
\-\ dilatation\\:\\ 0\\.0011057448156608452\ \(0\)\
\-\ mildly\\:\\ 0\\.0010988432039229074\ \(0\)\
\-\ external\\:\\ 0\\.001097142172003144\ \(0\)\
\-\ etiology\\:\\ 0\\.0010920958311294302\ \(0\)\
\-\ and\\/or\\:\\ 0\\.0010904322877082434\ \(0\)\
\-\ distress\\:\\ 0\\.0010871324475717128\ \(0\)\
\-\ oral\\:\\ 0\\.0010871324475717128\ \(0\)\
\-\ multiple\\:\\ 0\\.001086839374081684\ \(0\)\
\-\ just\\:\\ 0\\.0010774439468013322\ \(0\)\
\-\ rule\\:\\ 0\\.0010774439468013322\ \(0\)\
\-\ around\\:\\ 0\\.0010742823224452647\ \(0\)\
\-\ references\\:\\ 0\\.001072713839088651\ \(0\)\
\-\ administration\\:\\ 0\\.0010711534616253532\ \(0\)\
\-\ recommended\\:\\ 0\\.0010696011067037293\ \(0\)\
\-\ arteries\\:\\ 0\\.001068056692251202\ \(0\)\
\-\ after\\:\\ 0\\.0010676335764548323\ \(0\)\
\-\ foot\\:\\ 0\\.0010665201374482215\ \(0\)\
\-\ specific\\:\\ 0\\.0010665201374482215\ \(0\)\
\-\ levels\\:\\ 0\\.0010649913627028874\ \(0\)\
\-\ stable\\:\\ 0\\.0010634702896262095\ \(0\)\
\-\ especially\\:\\ 0\\.0010619568410079896\ \(0\)\
\-\ many\\:\\ 0\\.0010604509407933038\ \(0\)\
\-\ thyroid\\:\\ 0\\.0010574614869941759\ \(0\)\
\-\ family\\:\\ 0\\.0010574614869941759\ \(0\)\
\-\ pathology\\:\\ 0\\.0010559777868726695\ \(0\)\
\-\ appear\\:\\ 0\\.0010559777868726695\ \(0\)\
\-\ 12\\:\\ 0\\.0010559777868726695\ \(0\)\
\-\ fibrous\\:\\ 0\\.0010429427108264108\ \(0\)\
\-\ lymph\\:\\ 0\\.0010415285051161372\ \(0\)\
\-\ results\\:\\ 0\\.0010415285051161372\ \(0\)\
\-\ nausea\\:\\ 0\\.0010387198116794483\ \(0\)\
\-\ made\\:\\ 0\\.001027739242787276\ \(0\)\
\-\ symptomatic\\:\\ 0\\.0010250553818521172\ \(0\)\
\-\ diagnostic\\:\\ 0\\.0010223951675761042\ \(0\)\
\-\ currently\\:\\ 0\\.0010223951675761042\ \(0\)\
\-\ use\\:\\ 0\\.0010197581869092096\ \(0\)\
\-\ removal\\:\\ 0\\.00101714403753025\ \(0\)\
\-\ hypertension\\:\\ 0\\.00101714403753025\ \(0\)\
\-\ vs\\:\\ 0\\.0010158454016910622\ \(0\)\
\-\ extremities\\:\\ 0\\.0010119826748009929\ \(0\)\
\-\ similar\\:\\ 0\\.0010119826748009929\ \(0\)\
\-\ \\?\\:\\ 0\\.0010069080617827616\ \(0\)\
\-\ note\\:\\ 0\\.0009957927317336324\ \(0\)\
\-\ \\<\\:\\ 0\\.0009957927317336324\ \(0\)\
\-\ developed\\:\\ 0\\.000993377259913863\ \(0\)\
\-\ skin\\:\\ 0\\.0009909809587074208\ \(0\)\
\-\ 7\\:\\ 0\\.0009886035262101666\ \(0\)\
\-\ lungs\\:\\ 0\\.0009769893109843827\ \(0\)\
\-\ management\\:\\ 0\\.0009735904116713892\ \(0\)\
\-\ hospital\\:\\ 0\\.0009713455510169454\ \(0\)\
\-\ breath\\:\\ 0\\.000964709407683982\ \(0\)\
\-\ ago\\:\\ 0\\.0009603649821247731\ \(0\)\
\-\ appears\\:\\ 0\\.0009603649821247731\ \(0\)\
\-\ clear\\:\\ 0\\.0009539633493800257\ \(0\)\
\-\ could\\:\\ 0\\.0009518592825575338\ \(0\)\
\-\ intact\\:\\ 0\\.0009476946321552586\ \(0\)\
\-\ year\\-old\\:\\ 0\\.0009476946321552586\ \(0\)\
\-\ reported\\:\\ 0\\.000940541923483035\ \(0\)\
\-\ peripheral\\:\\ 0\\.0009335547469849387\ \(0\)\
\-\ 20\\:\\ 0\\.0009276917983565869\ \(0\)\
\-\ otherwise\\:\\ 0\\.0009267256139572297\ \(0\)\
\-\ weight\\:\\ 0\\.0009248024713589568\ \(0\)\
\-\ identified\\:\\ 0\\.0009219405317591549\ \(0\)\
\-\ then\\:\\ 0\\.0009181663280259933\ \(0\)\
\-\ would\\:\\ 0\\.0009181663280259933\ \(0\)\
\-\ involving\\:\\ 0\\.0009053162028995451\ \(0\)\
\-\ being\\:\\ 0\\.0008990905727054826\ \(0\)\
\-\ heart\\:\\ 0\\.0008964612466511999\ \(0\)\
\-\ inflammatory\\:\\ 0\\.0008947209976425193\ \(0\)\
\-\ liver\\:\\ 0\\.0008895596349132619\ \(0\)\
\-\ underwent\\:\\ 0\\.0008853248899390758\ \(0\)\
\-\ now\\:\\ 0\\.000881979344716681\ \(0\)\
\-\ does\\:\\ 0\\.0008803203714927555\ \(0\)\
\-\ fever\\:\\ 0\\.0008729657688864631\ \(0\)\
\-\ masses\\:\\ 0\\.0008721595404577558\ \(0\)\
\-\ 10\\:\\ 0\\.0008697536921337289\ \(0\)\
\-\ type\\:\\ 0\\.0008697536921337289\ \(0\)\
\-\ first\\:\\ 0\\.0008657860612276123\ \(0\)\
\-\ size\\:\\ 0\\.0008649987534356193\ \(0\)\
\-\ followed\\:\\ 0\\.0008649987534356193\ \(0\)\
\-\ white\\:\\ 0\\.000855707793693242\ \(0\)\
\-\ back\\:\\ 0\\.0008511673717836586\ \(0\)\
\-\ cancer\\:\\ 0\\.0008481779179845306\ \(0\)\
\-\ vascular\\:\\ 0\\.0008459550929721306\ \(0\)\
\-\ should\\:\\ 0\\.0008225267336620772\ \(0\)\
\-\ day\\:\\ 0\\.0008191303832587347\ \(0\)\
\-\ differential\\:\\ 0\\.0008191303832587347\ \(0\)\
\-\ adjacent\\:\\ 0\\.0008157718128424719\ \(0\)\
\-\ onset\\:\\ 0\\.0008144387759435839\ \(0\)\
\-\ while\\:\\ 0\\.0008117902294240076\ \(0\)\
\-\ bowel\\:\\ 0\\.0008091647140352534\ \(0\)\
\-\ examination\\:\\ 0\\.0008020600952519822\ \(0\)\
\-\ approximately\\:\\ 0\\.0007982541746846567\ \(0\)\
\-\ tenderness\\:\\ 0\\.0007846957496623288\ \(0\)\
\-\ some\\:\\ 0\\.0007834928302737798\ \(0\)\
\-\ diffuse\\:\\ 0\\.000781101274267909\ \(0\)\
\-\ see\\:\\ 0\\.0007699931193323635\ \(0\)\
\-\ decreased\\:\\ 0\\.0007671365950255312\ \(0\)\
\-\ ultrasound\\:\\ 0\\.0007654355631057678\ \(0\)\
\-\ from\\:\\ 0\\.0007647558654312876\ \(0\)\
\-\ abdomen\\:\\ 0\\.0007643068426617441\ \(0\)\
\-\ neck\\:\\ 0\\.000757621720114276\ \(0\)\
\-\ demonstrated\\:\\ 0\\.000757071250741838\ \(0\)\
\-\ wall\\:\\ 0\\.0007473306522459982\ \(0\)\
\-\ two\\:\\ 0\\.0007389285137729486\ \(0\)\
\-\ when\\:\\ 0\\.0007389285137729486\ \(0\)\
\-\ fluid\\:\\ 0\\.0007332847538055111\ \(0\)\
\-\ through\\:\\ 0\\.0007327768775425328\ \(0\)\
\-\ head\\:\\ 0\\.0007317636807288333\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0007312583544733896\ \(0\)\
\-\ ct\\:\\ 0\\.0007218017230628278\ \(0\)\
\-\ trauma\\:\\ 0\\.0007056185935259447\ \(0\)\
\-\ mild\\:\\ 0\\.0006794243520323481\ \(0\)\
\-\ who\\:\\ 0\\.0006726957757070356\ \(0\)\
\-\ over\\:\\ 0\\.0006568969173127906\ \(0\)\
\-\ more\\:\\ 0\\.0006452827020870066\ \(0\)\
\-\ physical\\:\\ 0\\.0006330027987866058\ \(0\)\
\-\ upper\\:\\ 0\\.0006226088482393473\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.0006219050428690347\ \(0\)\
\-\ chest\\:\\ 0\\.0006173698671671252\ \(0\)\
\-\ into\\:\\ 0\\.0006139270434660951\ \(0\)\
\-\ most\\:\\ 0\\.0005956627843381872\ \(0\)\
\-\ small\\:\\ 0\\.0005943765955257\ \(0\)\
\-\ can\\:\\ 0\\.0005852120629435596\ \(0\)\
\-\ present\\:\\ 0\\.0005827321116943481\ \(0\)\
\-\ year\\:\\ 0\\.0005773582543918567\ \(0\)\
\-\ \\'s\\:\\ 0\\.0005688546553040594\ \(0\)\
\-\ exam\\:\\ 0\\.0005667976871828315\ \(0\)\
\-\ large\\:\\ 0\\.000564173439562524\ \(0\)\
\-\ surgical\\:\\ 0\\.000542337491017951\ \(0\)\
\-\ seen\\:\\ 0\\.0005098513330518388\ \(0\)\
\-\ images\\:\\ 0\\.0004949468272793943\ \(0\)\
\-\ mass\\:\\ 0\\.0003588348450928637\ \(0\)\
\-\ an\\:\\ 0\\.0003567828696511865\ \(0\)\
